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Abstract 
Intracerebroventricular (ICV) administration of bombesin (BN) induces a 
syndrome characterized by stereotypic locomotion and grooming, 
hyperactivity and sleep elimination, hyperglycemia and hypothermia, 
hyperhemodynamics, feeding inhibition, and gastrointestinal function 
changes. Mammalian BN-like peptides (MBNs), e.g. gastrin-releasing 
peptide (GRP), Neuromedin C (NMC), and Neuromedin B (NMB), have been 
detected in the central nervous system. Radio-labeled BN binds to specific 
sites in discrete cerebral regions. Two specific BN receptor subtypes (GRP 
receptor and NMB receptor) have been identified in numerous brain regions. 
The quantitative 2-[14C]deoxyglucose ([14C]20G) autoradiographic 
method was used to map local cerebral glucose utilization (LCGU) in the 
rat brain following ICV injection of BN (vehicle, BN O.1Jlg, O.5Jlg). At each 
dose, experiments were conducted in freely moving or restrained 
conditions to determine whether alterations in cerebral function were the 
result of BN central administration, or were the result of BN-induced 
motor stereotypy. The anteroventral thalamic nucleus (AV) (p=O.029), 
especially its ventrolateral portion (AVVL) (p<O.0005), exhibited 
increased rates of metabolism under both restraint conditions. The effect 
was treatment dependent without interaction of the restraint conditions. 
Of all the regions that were reported to have high densities of BN 
receptors, the internal granular layer of the olfactory bulb (IGr) (p=O.028), 
and the suprachiasmatic nucleus (SCh) (p=O.003) exhibited BN treatment 
effects. BN effects on LCGU were also observed in the median eminence 
(ME) (p=O.011). Restraint, however, decreased LCGU in the lateral dorsal 
thalamic nucleus, ventrolateral and dorsomedial parts (LOVL and LOOM) 
(p=O.044, p=O.009), and the lateral geniculate (LG) (p=O.027). 
In sum, BN induced a marked and highly localized alteration in 
cerebral metabolism within parts of the anterior thalamus, which is the 
principle relay in the limbic circuitry. BN effects were also observed in 
IGr, Mi, SCh, and ME. Effects of restraint were found in LOVL, LOOM, and LG. 
It is suggested that increased LCGU in AV and AVVL may be the result of 
functional change in the limbic circuitry and the hypothalamus caused by 
BN receptor functional modification. In IGr, increased LCGU following BN 
administration is considered to be mainly the result the activation of NMB 
receptor, a subtype of BN receptors. In SCh, increased LCGU is believed to 
be caused both by BN effects on the thalamic, the hypothalamic, and the 
limbic functions and by activation of GRP receptor, another BN receptors 
subtype found in SCh. In ME, increased LCGU is suggested to be caused by 
BN effects on the hypothalamic functions, especially those related to the 
neuroendocrine functions. None of the alterations seen in these regions 
reflects the emission of stereotyped motor behaviors. Rather, they reflect 
a direct influence of BN central administration upon functioning of the 
cerebral regions influenced by BN administration. The restraint effects 
seen in LO, including LOOM and LOVL, are suggested to be the result of 
altered behavioral expression. The restraint effects seen in LG is 
suggested to be the result of reduced locomotion. 
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Chapter 1. Introduction 
Bombesin (BN) is a tetradecapeptide isolated from skin methanol extracts 
of a European amphibian of the family Discoglossidae, Bombina bombina 
(Anastasi et aI, 1971) (Table 1). Several mammalian BN-like peptides 
(MBNs), which have amino acid sequence homology with BN, have been 
detected in the mammalian central nervous system (CNS), as well as in 
the gastrointestinal tract (Moody et aI, 1986; Hernanz, 1990). The amino 
acid sequence of these MBNs and their structural homology with BN are 
shown in Table 1. 
Table 1. Structural homology of BN-like peptides 
Peptide Structural homology 
BN 
GRP 
NMC 
NMB 
pGlu Gin Arg Leu Gly Asn Gin Trp Ala Val 
Met Tyr Pro Arg - His 
His 
Leu Thr 
BN ---- bombesin; 
GRP ---- gastrin-releasing peptide, GRP14-27*; 
NMC ---- gastrin-releasing peptide(18-27), GRP18-27 ; 
NMB ---- neuromedin B 
- Identical amino acid sequence with bombesin; 
Gly His 
-
* Numbers refer to the amino acid position from the N-terminus. 
(modified from Ladenheim et aI, 1990). 
Bombesin central effects 
Leu Met NH2 
NH2 
NH2 
Phe NH2 
BN intracerebroventricular (ICV) injection produces a syndrome which 
includes stereotypic grooming and locomotion, reduced sleeping and 
resting (Kulkosky et aI, 1982; Rasler, 1984), and inhibited feeding (McCoy 
and Avery, 1990). It has been suggested that this BN syndrome may be 
mediated by a common mechanism involving endogenous MBNs (Moody et aI, 
1986; Hernanz, 1990). 
Being a complex fixed-action pattern, stereotypic grooming and 
locomotion represent an exterior manifestation of the cooperative 
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function of multiple CNS circuits (Kupfermann, 1991 c). Its execution 
requires an appropriate releaser, accurate movement maintenance, and 
appropriate termination. The accompanying sensory activation, 
proliferation of neuronal activity, and motor output may go far beyond any 
original localization of excitation and/or inhibition. Thus, a simple 
initiating factor, perhaps the activation of BN receptors, could lead to the 
involvement of multiple CNS systems in releasing behavioral stereotypy. 
Central BN administration also affects hemodynamics. ICV injection 
of BN is followed by increases in both blood epinephrine and 
norepinepherine, resulting in tachycardia, and elevated blood pressure 
(Carver-Moore et aI, 1991; Okuma et aI, 1991). Central BN administration 
induces neuroendocrine changes and hyperglycemia. Furthermore, BN 
induces hypothermia under conditions of cold ambient temperature (4°C) 
(Brown et aI, 1979), food deprivation, or insulin-induced hypoglycemia 
(Avery and Calisher, 1982; Babcock and Barton, 1989; Babcock et aI, 
1991). 
Localization of mammalian bombesin-like receptors in the eNS 
Perikaryal BN-like peptides have been localized in numerous cerebral 
regions (Panula et aI, 1982, 1984; Costello et aI, 1991; Watts and 
Swanson, 1987; Wada et aI, 1990; Battey and Wada, 1991). BN receptors 
also have a widespread distribution (Zarbin et aI, 1985, Wada et aI, 1991). 
In vitro autoradiography, using iodine 125 labeled tyrosine BN ([125 1_ 
Tyr4]BN) to mark BN receptors, revealed numerous regions showing high 
(1 25 1-Tyr4]BN densities (Table 2) (Zarbin et aI, 1985; Moody et aI, 1988). 
Binding was competitive, specific, saturable and reversible (Moody et aI, 
1978). In vitro binding of iodine 125 labeled gastrin-releasing peptide 
(GRP) to rat brain membranes confirms the existence of a specific 
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receptor for GRP in the brain (Hollingsworth, 1989). 
Table 2. [125 1_ Tyr4]BN binding sites in the eNS 
High binding level: 
olfactory bulb and tubercle, nucleus accumbens, suprachiasmatic 
periventricular nuclei of the hypothalamus 
central medial thalamic nucleus 
medial amygdaloid nucleus, hippocampus, dentate gyrus, subiculum 
nucleus of the solitary tract, substantia gelatinosa 
Moderate binding level: 
parietal cortex, deep layers of neocortex, entorhinal cortex 
caudate putamen, stria terminalis, locus coeruleus 
parabrachial nucleus, facial nucleus 
Low binding level: 
globus palidus, lateral thalamus, midbrain 
Negligible binding level: 
cerebellum, corpus callosum 
(from Zarbin et ai, 1985; Moody et ai, 1988) 
The suggestion of specific receptors for BN and MBNs is well 
supported. Recent cDNA cloning studies demonstrate the existence of both 
neuromedin-B-prefering and gastrin-releasing-peptide-prefering BN 
receptors (Wada et aI, 1991; Battey and Wada, 1991). In situ hybridization 
further revealed the distinct regional expression of neuromedin B (NMB) 
receptor mRNA and GRP receptor mRNA in the rat brain (Table 3), 
indicating that these BN receptor subtypes may participate in distinct 
neural functions. Studies using BN antagonists have also suggested the 
existence of at least two receptor subtypes, and have characterized the 
kinetics of their binding with BN, NMB, and GRP (Jensen and Coy, 1991). 
Ligand displacement studies have revealed that the GRP receptor has a 
high binding affinity and relative low capacity, whereas the NMB receptor 
has a relatively high capacity but lower affinity (Narayan et aI, 1990). 
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Table 3. Distributions of GRP, NMB, GRP receptor, and NMB receptor 
mRNAs in the CNS rece~tor mRNA 
GRP NMB GAP NMB 
Tissue rece~tor rece~tor 
Forebrain 
Isocortex 
II ++ ++ 
III ++ + 
V + ++ 
VI + + 
Olfactory regions 
Main Bulb +++ 
Anterior olfactory n. ++ ( + ) +++ 
Hippocampal formation 
Dentate gyrus ++ ++ ++ ++ 
Amygdala 
Amygdaloh ippocampal area ++ ( + ) +++ 
N. lateral olfactory tract +++ ( + ) 
Basal ganglia 
N. accumbens + + 
Magnocellular n. + +++ + 
Thalamus 
Paraventricular n. +++ 
Central median. and central lateral n. +++ 
Hypothalamus 
Supraschiasmatic n. ++ +++ 
Supraoptic n. ( + ) ++ 
Paraventricular n. + ++ ( + ) 
Medial preoptic n. ++ +++ 
Lateral mammillary n. +++ 
Brainstem 
N. solitary tract + + + + 
N ambiguus + + + + 
Central gray + + + 
The strength of hybridization signal is graded based on the grains per 
positive cell. +++ Strong signal; ++ moderate strong; + weak signal; 
(+) very weak signal; - no signal over the background. Abbreviation: 
n.= nucleus. (From Battey and Wada, 1991) 
However, the studies mentioned above have a common limitation. They 
could only provide possible sites of initial interaction between BN and the 
CNS. They can not reveal BN effects at sites remote from BN perikaryon, or 
terminal fields. Considering that the CNS functions as an interconnected 
network of neural circuits, the complex integrated behaviors induced by 
BN probably involve many cerebral regions. A fuller description of BN 
effects in the CNS requires mapping of BN influences upon functional 
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activity over large areas of the CNS. The mapping may not only show the 
locations of pharmacologically relevant BN receptors, but also sites 
influenced by subsiquent to the activation of BN receptors. 
Research strategy 
There is a method which allows the mapping of regional functional 
activity following BN administration. The quantitative 2-[14C]deoxyglucose 
([14C]2DG) autoradiographic method has been used extensively to examine 
changes in local cerebral glucose utilization (LCGU) resulting from many 
types of experimental treatments (Sokoloff, 1981; Sokoloff et aI, 1989). 
Since glucose is the major energy source of neurons, glucose utilization 
can be considered to be a direct reflection of cellular energy consumption 
levels. Combining information on the distribution of MBN-containing 
neurons and BN receptors, with data from a metabolic study demonstrating 
functional effects of BN administration, we may be able to put together a 
more detailed picture of the sites of BN central actions. 
Strategy for mapping local cerebral glucose utilization 
The [14C]2DG method maps functional activity in a large number of cerebral 
regions. Each region is an independent experiment. Thus, a large scale map 
of the brain is composed of many experiments. Given the large number of 
experiments, there is a high probability of type error over entire body of 
data. Therefore, we would like to reduce the chance of type I error 
occurring among the areas of greatest interest, by placing this small 
number of regions into a distinct category. 
The anterior thalamus is the principle synaptic relay connecting 
subcortical limbic structures with the limbic cortex (Kelly and Dodd, 
1991; Kupfermann, 1991 a). Preliminary studies in our laboratory have 
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indicated that the anteroventral thalamic nucleus, especially its 
ventrolateral portion, shows increased metabolism after ICV injection of 
BN (0.5 1l9/51l1), while other regions that show high receptor binding 
densities were unaffected (Ramm, unpublished data). Therefore, we 
intended to pay particular attention to LCGU in the anterior thalamus, and 
we define its subdivisions as the primary structures of interest. The 
subdivisions of the anterior thalamus include: anterodorsal thalamic 
nucleus, anteromedial thalamic nucleus, anteroventral thalamic nucleus, 
and its ventral lateral portion (Table 4). 
Table 4. Primary regions: subdivisions of the anterior thalamus 
Cerebral Regions 
anterodorsal thalamic nucleus 
anteromedial thalamic nucleus 
anteroventral thalamic nucleus 
anteroventral thalamic nucleus, ventral 
lateral part 
Abbreviations 
NJ 
AM 
AV 
AWL 
We define secondary structures as those which exhibit high 
concentrations of BN receptors (Zarbin et aI, 1985; Moody et aI, 1988; 
Wada et aI, 1991; Battey and Wada, 1991) (Table 5). 
Table 5. Secondary regions: BN binding sites 
Cerebral Regions 
internal granular layer of the olfactory bulb 
mitral cell layer of the olfactory bulb 
olfactory tubercle 
deep layer of neocortex 
accumbens nucleus 
basolateral amygdaloid nucleus anterior part 
lateral amygdaloid nucleus 
medial amygdaloid nucleus 
posteromedial cortical amygdaloid nucleus 
dentate gyrus 
subiculum 
stria termilalis nucleus 
mediodorsal thalamic nucleus 
periventricular hypothalamic nucleus 
suprachiasmatic nucleus 
locus coeruleus 
nucleus of the solitary tract 
substantia gelatinosa 
Abbreviations 
IGr 
Mi 
Tu 
NcDL 
Acb 
BLA 
La 
MeA 
PMCo 
m 
S 
Sf 
MD 
Pe 
&l1 
L.C 
Sol 
SubGel 
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Tertiary structures include limbic structures other than the anterior 
thalamus; regions immediately surrounding the anterior thalamus, and 
hypothalamic regions involved in the regulation of homeostasis. Three 
subcortical visual regions were also included since they have been 
reported to be affected by immobilization (Bryan Jr, 1983) (Table 6). 
Table 6. Tertiary regions: limbic regions, thalamic regions, 
hypothalamic regions, subcortical visual pathways 
Cerebral Regions Abbreviations 
cingulate cortex area 1 Cg1 
cingulate cortex area 2 Cg2 
cingulate cortex area 3 Cg3 
hippocampus Hi 
entorhinal cortex Ent 
lateral mammillary nucleus LM 
medial mammillary nucleus MM 
laterodorsal thalamic nucleus, dorsal medial LOOM 
laterodorsal thalamic nucleus, ventral lateral LOVL 
ventral lateral thalamic nucleus VL 
ventromedial thalamic nucleus VM 
ventral posterolateral thalamic nucleus VPL 
ventral posteromedial thalamic nucleus VPM 
ventromedial hypothalamic nucleus VMH 
dorsal medial hypothalamic nucleus OM 
lateral hypothalamic area LH 
posterior hypothalamic area PH 
arcuate hypothalamic nucleus Arc 
infundibular stem InfS 
median eminence ME 
lateral geniculate LG 
oculomotor nucleus 3 
superior colliculus ~ 
By organizing the cerebral regions into three categories, we still face 
the possibility of encountering significant findings purely by chance. 
Using this categorization, however, we can decrease the number of regions 
tested within each category. Now that our primary interest regions only 
need four tests, the p values can be examined with greater confidence that 
they are not a statistical artifact. 
To determine if BN affects overall brain metabolic rate, we also 
investigated whole brain weighted cerebral glucose utilization. 
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Effects of motor stereotypy on local cerebral glucose utilization 
In examining the effects of BN on LCGU, there is the possibility that 
alterations in metabolism could result from the direct actions of BN on 
neural functions. Observed alterations in metabolism could also result 
from the motor stereotypy associated with BN administration. 
Furthermore, there is the possibility of an interaction effect, in which the 
BN treatment effect depends upon the restraint effect, or vice versa 
(Figure 1). Therefore, the experimental conditions needed to include both 
freely moving animals, and animals that were prevented from emitting 
motor stereotypy. A condition of complete physical restraint was thus 
used to allow examination of effects due to behavioral stereotypy, as well 
as those due to the interaction effects between BN treatment and the 
restraint conditions (unrestrained and restrained). By prohibiting the 
animals from performing locomotor and grooming behaviors, the restraint 
condition allows possible BN treatment effects to be distinguished from 
the effects of motor stereotypy. 
:::> 
(!) 
U 
...J 
Unres~rained 
....-------
~ed 
BN dose 
A 
x 
BN dose 
D 
No Significant Inter action 
B c 
Significant Inter action 
• • • 
E F 
Figure 1. Example of possible scenarios of BN effects and restraint effects. The top 
three illustrate cases in which there is no interaction. The bottom three illustrate 
interaction effects. The rate of LCGU is not differentially affected by BN dose in 
restrained and unrestrained animals (Modified from Walsh, 1990; Daniel, 1991). 
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The classic [14C]2DG method uses a pelvic plaster cast to immobilize 
the animal to facilitate the blood sampling procedures (Sokoloff, 1977). 
Increased stress caused by the pelvic plaster cast is an undesired side 
effect (Crane and Porrino, 1989). Our study requires complete restraint. 
We therefore designed a restraint jacket (Figure 3) using cloth material to 
"wrap up" the animal, and establish a reliable yet minimally stressful 
restraint condition. This jacket was considered to be more comfortable 
for the animal than other forms of restraint (plastic restrainer, or the 
plaster cast). 
In sum, central BN administration causes a pharmacological syndrome 
characterized by stereotypic grooming and locomotion, hyperglycemia, 
hypothermia, hyperhemodynamics, neuroendocrine effects, and feeding 
inhibition. These behavioral and physiological changes may be mediated by 
BN receptors distributed in numerous brain regions. The [14C]2DG method 
can be used to map regional cerebral metabolism following central BN 
administration. The objectives of the experiment were: 1) to investigate 
cerebral metabolism in the regions that have been linked to BN-induced 
behavioral stereotypy; 2) to investigate correlations between BN receptor 
distribution and regional cerebral metabolic alterations; 3) to investigate 
whether other cerebral regions were functionally involved in the BN-
induced effects. In order to distinguish effects caused by BN receptor 
activation from those caused by motor stereotypy, animals were run under 
both restrained and unrestrained conditions. 
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Chapter 2. Literature Review: 
The mediation of BN central effects 
Following central BN administration, BN interacts with its receptors in 
the CNS. The effects of the interactions are twofold. Initially, the 
functional state of the cells endowed with BN receptors is modified. 
However, the scope of behavioral and physiological changes involved in the 
BN syndrome suggests involvement of many brain regions. Therefore, it is 
likely that there is synaptic transmission of the initial BN effects on BN 
receptors to other brain regions, where BN receptors may be absent. 
Behaviorally, the BN syndrome involves excessive stereotypic 
grooming and locomotion (Kulkosky et aI, 1982; Rasler 1984). At the 
physiological level, increased blood glucose levels (Brown et aI, 1979), 
lowered body temperature set point (Stump et aI, 1990; Avery et aI, 1981; 
Babcock et aI, 1989), agitated hemodynamics (Freeman et aI, 1991), and 
altered enterogastric activities (Schubert et aI, 1991; Strephens et aI, 
1991; Heymann-Monnikes et aI, 1990) are observed. The BN syndrome also 
includes feeding inhibition (McCoy and Avery, 1990). 
In this . chapter, the literature on BN central effects will be reviewed 
in the light of BN receptor mapping studies. We will also discuss possible 
functional connections between regions containing BN receptors and other 
brain regions which may be involved in mediating BN effects. At the end of 
the chapter, some of the theoretical concerns of the [14C]2DG method will 
be examined. 
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I. Mapping of mammalian BN-like peptides and BN receptors 
in the eNS 
Radioimmunoassay and immunohistochemical analyses have shown a wide 
distribution of two mammalian BN-like peptides (MBNs), i.e. gastrin-
releasing peptides (GRP) and neuromedin B (NMB), in the rat brain (Panula 
ef aI, 1982, 1984; Moody ef aI, 1986; Watts and Swanson, 1987). /n situ 
hybridization studies performed with cDNA probes specific for NMB or GRP 
mRNA in the brain have confirmed that GRP and NMB exist throughout the 
whole eNS (Wada et aI, 1990). NMB mRNA is found most prominently in the 
olfactory bulb, dentate gyrus, and dorsal ganglion. In contrast, the highest 
levels of GRP mRNA are observed in the isocortex and hippocampal 
formation, including the hippocampus proper, dentate gyrus, and subiculum 
(Tables 3, 7) (Wada et aI, 1990, Battey and Wada, 1991). The 
heterogeneous distribution of the various MBNs suggests that these 
structurally related neuropeptides have distinct functions. 
Table 7. Distribution of strong cell expression of 
NMB mRNA and GRP mRNA 
Cerebral regions NMB mRNA GRP mRNA 
the olfactory bulb + + + 
central thalamic regions + + + 
dentate gyrus + + + 
dorsal root ganglion + + + 
isocortex + + + 
hippocampal formation + + + 
+++ Very high density of mRNA expression; 
- No distribution. 
(From Wad a et ai, 1991) 
Just as BN-like peptides have been localized in numerous brain 
regions, BN receptors also have a widespread distribution (Zarbin et aI, 
1985). /n vitro autoradiographic techniques to detect binding of [125 1_ 
Ty r4]BN to BN receptors have shown several regions that have high 
receptor densities (Moody et aI, 1978; Wolf and Moody, 1985; Zarbin et aI, 
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1985; Moody et aI, 1988; Moody et aI, 1990) (Table 2). Binding is specific, 
saturable and reversible (Moody et aI, 1978). In vitro binding of iodine 125 
labeled GRP ([1251]GRP) to rat brain membranes has identified a high 
concentration of GRP receptors in the hippocampus, cortex, and striatum 
with high affinity (Hollingsworth, 1989). 
Antibodies raised against BN block BN effects, indicating that BN 
effects are mediated by specific receptors (Merali et aI, 1988b). Both 
central and peripheral administration of anti-BN antiserum have been 
shown to attenuate the effects of BN on feeding. Central anti-BN 
antiserum administration completely antagonizes the effect of BN on 
grooming (Merali et aI, 1988b). 
Ligand displacement studies have revealed functional variation 
between BN receptors. The GRP receptor, for example, has a high binding 
affinity and relatively low capacity (Narayan et aI, 1990). In contrast the 
NMB receptor has a lower affinity and high capacity. Relative binding 
affinities of BN analogs are in the order of GRP > NMC ~ BN ~ GRP1-27 > NMB 
(Narayan et aI, 1990). Two BN receptor antagonists, [D-Arg1 D- Trp7,9 
Leu 11]SP (spantide) and [Leu 13 "'( C H2NH) Leu14]BN (",SN, the 'II symbol 
indicates substitution of a reduced peptide bond at the indicated site, i.e. 
CONH changes to CH2NH) also inhibit specific binding of 1251-GRP in a dose-
dependent manner (Narayan et aI, 1990). Functional variation of the 
receptors, as well as their structural homology may be responsible for the 
cross-sensitivity and limited specificity of the GRP receptors and NMB 
receptors. 
[125 1_ Tyr4]BN and [125 1_ Tyr4]NMB binding studies have demonstrated 
that BN receptor heterogeneity exists within individual nuclei (Ladenheim 
et aI, 1990). The nucleus accumbens exhibits high binding densities of 
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[ 125 1_ Tyr4]BN but not [125 1_ Tyr4]NMB. This binding is totally inhibited in the 
presence of BN, but only partially inhibited by NMB (Ladenheim et aI, 
1990), indicating that the predominant BN receptor in this region may be 
of the GRP type. The olivery nucleus shows similar receptor heterogeneity. 
In contrast to these different BN and NMB binding patterns, equivalent 
[ 125 1_ Tyr4]BN and [125 1_ Tyr4]NMB binding densities are observed in the 
nucleus of the solitary tract and paratrigeminal nucleus. This binding is 
inhibited in the presence of either BN or NMB (Ladenheim et aI, 1990), 
indicating that the predominant BN receptor in this region may be of the 
NMB type. It has been suggested that the receptor heterogeneity found 
within various regions is associated with variation in regional response 
to central BN administration (Johnston and Merali, 1988 a,b). 
Isolation of the GRP receptor and NMB receptor cDNA clones, from 
murine embryo fibroblasts and human lung carcinoma cells, provides the 
means to study BN receptor expression in the brain (Corjay et aI, 1990, 
1991; Battey et aI, 1991; Wad a et aI, 1991). In situ hybridization studies 
of rat brain mRNA expression, using both NMB and GRP receptor probes, 
have shown the locations of BN receptor synthesis (Tables 3, 8) (Battey 
and Wada, 1991; Wada et aI, 1991). Overall, NMB receptor mRNA expression 
is greatest in the olfactory and central thalamic regions, while GRP 
receptor mRNA expression is most prominent in the hypothalamus (Wada 
et aI, 1991). 
Table 8. Distribution of cell expression of NMB receptor mRNA 
and GRP receptor mRNA 
Brain regions 
tenia tecta 
anterior olfactory nucleus 
nucleus of the lateral olfactory tract 
bed nucleus of the accessory olfactory tract 
accessory olfactory bulb 
piriform cortex 
frontal cortex 
isocortex 
rhomboid 
dentate gyrus 
amygdalopiriform nucleus 
lateral mammillary nucleus 
field CA3 of Ammon's horn 
medial amygdaloid nucleus 
nucleus ambiguus 
anterodorsal thalamic nucleus 
central medial thalamic nucleus 
central lateral thalamic nucleus 
paraventricular nucleus 
suprachiasmatic nucleus 
magnocellular preoptic nucleus 
lateral hypothalamic area 
supraoptic area 
dorsal raphe nucleus 
++ High density mRNA expression; 
+ Medium density mRNA expression; 
- No expression. 
(From Wada et aI, 1991) 
II. BN effects on animal behaviors 
NMB GP 
receptor receptor 
mRNA mRNA 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
+ 
+ 
++ + 
++ 
++ 
++ 
++ 
++ 
++ 
+ 
+ 
+ 
++ 
++ 
++ 
+ 
+ 
Intracerebroventricular (leV) injection of BN induces behavioral 
stereotypy characterized by excessive grooming and overt locomotion 
(Kulkosky et aI, 1982; Rasler, 1984). The animals appear to be trapped in a 
constantly activated state. Brief moments of sitting or lying always 
terminate with an abrupt burst of grooming or locomotor activity. The 
grooming appears compulsory (Rasler, 1984). Electroencephalographic 
analysis of BN injected rats reveals desynchronized or activated patterns 
consistent with the wakeful state (Rasler, 1984). 
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BN is not the only peptide that causes excessive stereotypic grooming 
and locomotion when given centrally (Cowan et aI, 1985; Van Wimersama 
Greidanus, 1984; 1985 a, b; 1986; 1989). In rats, ICV injection of 
adrenocorticotropic hormone (ACT H) causes a dose-related behavioral 
stereotypy characterized by scratching (Cowan et aI, 1985; Van 
Wimersama Greidanus, 1985a). ICV thyrotropin-releasing hormone (TRH) 
administration results in excessive grooming characterized by scratching 
and paw licking (Cowan et aI, 1985; Van Wimersama Greidanus et aI, 
1989). In mice, ICV substance P (SP) administration (20 Jlg) induces both 
grooming and scratching behaviors for only 12 min, while BN (0.1 Jlg) 
induces enhanced grooming for about 2.5 hr (Meisenberg and Simmons, 
1986) . 
In the rat, combined central administration of BN with TRH, or with a 
submaximal dose of ACTH does not result in more intense behavioral 
stereotypy than with single peptide treatment (Van Wimersama Greidanus 
et aI, 1988). Tolerance (attenuated response beyound certain dose level) 
occurs for the effect of ACTH but not for that of BN. No cross-tolerance 
(attenuated response beyound certain dose level of other peptide) exits 
between BN and ACTH (Van Wimersama Greidanus et aI, 1985), indicating 
that the behavioral effects of these peptides are mediated by their 
specific receptors (Gmerek and Cowan, 1983). However, due to certain 
similarities of the behavioral stereotypy, the mediation of the behavioral 
stereotypy induced by various peptides may share some common neural 
mechanism(s). 
Locomotor and grooming behaviors are fixed-action patterns 
consisting of a combination of simpler fixed-action patterns performed in 
sequence (Kupfermann, 1991 c). In rats, grooming behavior involves 
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movements of the head, directed toward the limbs, body, and tail, and 
movements of the fore- and hind-limbs, directed towards the head, body 
and tail. Grooming of the face is associated with two stereotypic motor 
patterns, including licking, single or parallel strokes with the forepaw. 
The various patterns do not occur in a random sequence, but rather in a 
relatively predictable order (Kupfermann, 1991 c). 
The distribution of BN receptors, and the effects of localized 
injection of BN indicate that numerous brain regions may be associated 
with initiating and/or maintaining BN-induced behavioral stereotypy, and 
with the physiological effects of BN. Since individual eNS regions are 
incorporated into complex neural circuits containing multiple brain 
regions (Kupfermann, 1991 c), BN receptors in various cerebral regions 
may contribute to the behavioral and physiological effects of BN. 
BN receptor distributions in limbic circuits 
The limbic system, and the hypothalamic regions are characterized by 
widespread distributions of BN receptors in high concentrations (Tables 2, 
3, 8) (Zarbin et aI, 1985; Moody et aI, 1988; Wada et aI, 1991; Battey and 
Wada, 1991). In the limbic regions, GRP receptors are distributed in the 
dentate gyrus, fields CA3 of Ammon's horn, lateral mammillary nucleus, 
medial amygdaloid nucleus, and nucleus accumbens, whereas NMB 
receptors are distributed in the dentate gyrus, amygdalohippocampal area, 
and anterodorsal thalamic nucleus (Tables 3, 8) (Wada et aI, 1991; Battey 
and Wada, 1991). The hypothalamic regions contain GRP receptors almost 
exclusively. These regions include: the suprachiasmatic nucleus, 
supraoptic nucleus, paraventricular nucleus, and medial preoptic nucleus 
(Tables 3, 8) (Wada et aI, 1991; Battey and Wada, 1991). 
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The limbic lobe was first suggested to form a neural circuit that 
provides the anatomical substratum for emotions by James Papez in 1937 
(Isaacson, 1974; Mclean, 1976). In the limbic circuits, the anterior 
thalamus receives afferents from the cingulate cortex, hippocampal 
formation and mammillary complex of the hypothalamus (Figures 2, 18, 
19). These various connections of the anterior thalamus complete circuits 
linking the hippocampal formation and hypothalamus with the cingulate 
(i.e. limbic) cortex (Kupfermann, 1991 a; Faull and Mehler, 1985). 
I Prefrontal cortex Association cortex 
l + A~ 
I Ongulate gyrus I 
A ~ , 
" 
Cingulum Hippocampal 
formation 
Anterior 
thalamic ~ + 
nuclei .... Fornix I Amygdala 
Mammillo-A ~ 
thalamic ,~ 
tract 
Mammilary 
complex 
... 
Hypothalamus 
.... 
... 
Figure 2. A proposed neural circuit for the limbic system. The circuit 
originally proposed by James Papez is indicated by thick lines; more 
recently described connections are shown by fine lines. Known 
projections of the fornix to hypothalamic regions (mammillary bodies 
and other hypothalamic areas) and of the hypothalamus to the 
prefrontal cortex are indicated. A pathway interconnecting the 
amygdala to limbic structures is shown. Reciprocal connections 
between the hippocampal formation includes the hippocampus proper 
and surrounding structures, including entorhinal cortex and the 
subicular complex (Modified from Kupfermann, 1991 a). 
I 
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The limbic system can be parceled into three main cortico-
subcortical subdivisions (Maclean, 1986) (Figures 2, 18, 19). Two 
telencephalic nuclear groups located in the amygdala and the septum are 
centers for two of these subdivisions. The amygdala division has been 
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shown to be involved in feeling and expressive states essential for self-
preservation (i.e., feeding, fighting, and self-protection) . The septal 
division has been found to be implicated in feeling and emotional 
expressive states. The thalamocingulate division is so referred to because 
the afferent supply to the mesocortical areas derives from the thalamus. 
The laterodorsal thalamic nucleus, including the dorsomedial part and 
ventrolateral part, is a neothalamic nucleus linked to the limbic system. 
It lies just caudolateral to the anterior thalamus and peripheral to the 
internal medullary lamina (Faull and Mehler, 1985). The laterodorsal 
thalamic nucleus has reciprocal projections to the cingulate cortex 
(Maclean, 1986; Faull and Mehler, 1985). Its functions may be linked to 
emotional expression in mammals (Kelly and Dodd, 1991). 
Afferent fibers to the anterior thalamus are contained in three major 
neural projections: the fornix, mammillothalamic tract (tract of Vicq-
d'Azyr), and thalamocingulate fibers. Neural fibers from these projections 
usually go to specific anterior thalamic subdivisions (Figure 2) (Maclean, 
1986): the anteroventral thalamic nucleus (AV), anteromedial thalamic 
nucleus (AM), and anterodorsal thalamic nucleus (AD). Hippocampal 
projections to the anterior thalamus arise from the subicular complex and 
pass via the fornix mainly to AV and AM (Faull and Mehler, 1985). The 
mammillary complex projects via the mammillothalamic tract to AV, AM 
and AD; in particular , the medial mammillary nucleus projects 
(bilaterally) to AD (Faull and Mehler, 1985). The thalamocingulate tract is 
largely composed of reciprocal fibers between the anterior thalamus and 
the cingulum. Afferents from the anterior thalamic regions project in a 
topographic fashion onto the medial (cingulate) cortex and also onto the 
presubiculum (Faull and Mehler, 1985). AV and AM also receive projections 
from both the cingulate and retrosplenial cortices. (Maclean, 1986). 
The anterior thalamus is composed of three cytologically distinct 
nuclei, AD, AV, and AM. These nuclei can be identified by their marked 
differences in acetylcholinesterase (AChE) staining intensity (Faull and 
Mehler, 1985; Paxinos and Watson, 1989). AV is especially prominent and 
well delineated in AChE stained material; it displays intense AChE 
activity, especially in its ventrolateral portion (AVVl). AD and AM are 
characterized by moderate and low levels of AChE activity, respectively. 
AM is composed of small to medium sized cells which stain less intensely 
than those in AD. AV is also characterized by its cellular density; the 
cells are closely packed, except in the caudal ventromedial region where 
they are often dispersed by fiber fascicles from the mammillothalamic 
tract (Faull and Mehler, 1985). 
The mammillothalamic tract is a key neural pathway in the limbic 
circuitry. It has been reported that lesions of the mammillothalamic tract 
in the rat reduce retention in a two-way active avoidance task (Isaacson, 
1974). Attenuated retention is believed to be the result of the animal's 
inability to perform the task due to transmission interruption. 
Amphetamine improves the active avoidance performance of normal 
animals as well as those with the mammillothalamic tract lesions 
(Isaacson, 1974), suggesting retention of the avoidance task can be 
improved by facilitation of behavior itself. The drug also enhances 
locomotor behavior and reduces "freezing" (Isaacson, 1974). Furthermore, 
the behaviors of the animals with mammillothalamic tract lesions (slow 
or reluctant to begin new behavioral acts) is similar to the behavioral 
changes caused by lesions of the limbic system which affect the animals' 
willingness to initiate or continue behavioral sequences (Isaacson, 1974). 
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Localized BN injection 
Localized injections can deliver ligands (BN, MBNs, and BN antagonists) 
directly into regions containing BN receptors. There are several cerebral 
regions that are sensitive to BN administration. BN micro-injection into 
the hypothalamic areas, amygdala, periaqueductal gray, septum, ventral 
tegmantal areas, reticular formation (Kyrkouli et aI, 1987), and nucleus 
accumbens (Moody et aI, 1988) increases grooming behavior and decrease 
the time spent resting and sleeping. 
However, due to the receptor heterogeneity between various brain 
regions and within individual nuclei, not all of the regions are equally 
sensitive. For example, the nucleus accumbens contains only GRP 
receptors, whereas the nucleus of the solitary tract contains both GRP and 
NMB receptors (Battey and Wada, 1991). It has been shown that BN 
(0.0001-1.0 ~g) administrated into the nucleus accumbens did not 
significantly affect grooming or satiety, whereas both grooming and 
satiety were markedly increased by BN (0.0001-1.0 ~g) micro-injection at 
the nucleus of the solitary tract (Johnston and Merali, 1988 a,b). 
Monoaminergic system and BN effects 
Central BN administration changes the functions of the tuberoinfundibular 
dopaminergic system (Manzanares et aI, 1991). ICV BN has been 
demonstrated to cause a dose- and time-related increase in the activity 
of dopamine neurons projecting to the median eminence and intermediate 
lobe of the pituitary, and a corresponding increase in plasma growth 
hormone, and decreases in plasma prolactin and a-melanocyte-stimulating 
hormone (Houben and Denef, 1990). The stimulatory actions of GRP, NMC, 
and NMB on the anterior pituitary functions can be blocked by the BN 
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receptor antagonist ",BN (Houben and Oenef, 1990). These effects are 
thought to be mediated through GRP receptors in the parvocellular neurons 
located in the paraventricular nuclei (Manzanares et aI, 1991; Wada et aI, 
1991), and possibly those in the periventricular nuclei (Zarbin et aI, 
1985). 
The meso limbic dopaminergic system may also be affected by central 
BN administration. Although BN receptors have not been found in this 
system, voluntary movement coordination is associated with the function 
of the mesolimbic system (Role and Kelly, 1991). Since the BN-induced 
behavioral stereotypy involves accurate voluntary movement coordination, 
the mesolimbic dopaminergic system may play a role in the execution of 
the behavioral stereotypy induced by BN. 
These suggestions are supported by several studies on the effects of 
BN on the meso limbic dopaminergic system. Central BN administration 
increases the accumulation of dopamine metabolites in the striatum, 
olfactory tubercles, and hypothalamus, indicating increased dopamine 
turnover (Widerlov et aI, 1984; Merali et aI, 1985). When dopaminergic 
neurons are lesioned using 6-hydroxydopamine (6-0HOA, ICV), the 
behavioral effects of central BN are markedly attenuated or absent (Merali 
et aI, 1985). Haloperidol [a dopamine receptor 1 (0 1 ) and dopamine 
receptor 2 (02 ) antagonist] has been shown to attenuate BN-induced 
behavioral stereotypy without changing the relative distribution of 
behavioral elements (Schultz et aI, 1984; Van Wimersama Greidanus et aI, 
1985; 1986). However, BN-induced behavioral stereotypy is unaffected by 
behaviorally nondepressant doses of haloperidol, morphine, and 
neurotensin (Meisenberg and Simmons, 1986), indicating that the 
mesolimbic dopaminergic system has a facilitating function in modulating 
BN-induced behavioral stereotypy. 
Both 0 1 and O2 receptor based mechanisms participate in the 
modulation of BN behavioral effects (Merali and Piggins, 1990). The roles 
of 0 1 and O2 receptors differ in the modulation of BN-induced behaviors. 0 1 
is more involved with grooming and O2 with locomotion, although both are 
required for the full expression of these behaviors (Piggins and Merali, 
1989) . 
Serotonergic system. The raphe nuclei of the midbrain and upper pons 
project primarily in the medial forebrain bundle to an array of rostral 
sites, including the cerebral cortex, striatum, limbic structures, olfactory 
tubercle, hippocampus, and diencephalon (Role and Kelly, 1991). 
The dorsal raphe nucleus expresses NMB receptor mRNA (Wad a et aI, 
1991). Activation of BN receptors using BN, GRP, and NMB depolarize a 
subpopulation of dorsal raphe 5-HT neurons by acting on postsynaptically 
located receptors (Pinnock and Woodruff, 1990 a,b; Wada et aI, 1991). 
Thus, the serotonergic system · may also participate the modulation of BN 
induced behavioral stereotypy. 
III. Bombesin effects on physiological functions 
The effects of BN central administration on physiological functions 
reflect its effects on the hypothalamus. Both [1251]BN binding studies and 
in situ cDNA hybridization maps of BN receptors indicate BN receptors in 
the suprachiasmatic nucleus, paraventricular nucleus, preoptic nucleus, 
supraoptic nucleus, lateral mammillary bodies, and periventricular 
nucleus (Zarbin, 1989; Wada et ai, 1991; Battey and Wada, 1991). 
Therefore, BN effects on physiological functions may be mediated by 
hypothalamic BN receptors. 
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BN effects on neuroendocrine functions 
Central BN administration affects the release of pituitary hormones. 
These activation are exerted via GRP receptors on the magnocelullar 
neurons in the paraventricular and supraoptic nuclei, and the parvocellular 
neurons in the paraventricular nucleus (Wada et aI, 1991), and possibly the 
periventricular nucleus (Zarbin et aI, 1985; Moody et aI, 1988). 
Functional modification of the paraventricular nuclei and supraoptic 
nuclei may cause increased vasopressin and oxytocin release from the 
magnocellular neurons (Armstrong, 1985; Kupfermann, 1991 a), which is 
partially responsible for increased blood pressure following BN 
administration. 
Functional modification of the paraventricular, and possibly 
periventricular nuclei causes the release of various inhibiting-releasing 
hormones from the parvocellular neurons. These inhibiting-releasing 
hormones are in turn transferred from the median eminence to the 
anterior pituitary through the pituitary portal system (Armstrong, 1985; 
Kupfermann, 1991 a). Increases in plasma cortisone and ACTH 
concentration (Sander, 1991; Malendowicz et aI, 1991), growth hormone 
(GH) (Bitar et aI, 1991; Houben and Denef, 1990), and thyroid stimulating 
hormone (TSH) (Malendowicz and Miskowiak, 1990) are the results of 
functional modification in the hypothalamic nuclei following central BN 
administration. 
BN effects on hemodynamics 
ICV BN administration elicits a hemodynamic response similar to that of 
stress (Freeman et aI, 1991). Increased blood epinephrine and 
norepinephrine are partially responsible for these reactions (Carver-Moore 
23 
24 
et aI, 1991; Okuma et aI, 1991). Lateral ventricle injection only induces an 
increase in blood epinephrine, but not norepinephrine (Okuma et aI, 1991). 
Intracerebral micro infusion of BN into specific brain regions elicits 
increases in peripheral blood epinephrine and norepinephrine (Carver-
Moore et aI, 1991). An increase in both blood epinephrine and 
norepinephrine can be elicited by BN infusion into the central nucleus of 
amygdala, anterior hypothalamus, parabrachial nucleus, and nucleus of the 
solitary tract. Among these regions, the amygdala, and nucleus of solitary 
tract have high levels of BN receptor mRNA expression (Wada et aI, 1991; 
Battey and Wada, 1991). 
BN and circadian rhythm regulation 
The suprachiasmatic nucleus has been identified as the primary biological 
clock which maintains CNS circadian rhythms (Kelly, 1991). Central BN 
administration affects a series of animal behaviors and physiological 
functions which have a circadian rhythm. [125 1_ Tyr4]BN binding studies 
support that there is high concentration of BN receptors in the 
suprachiasmatic nucleus. In situ hybridization studies confirm that the 
suprachiasmatic nucleus express GRP mRNA (Wada et aI, 1990) and GRP 
receptor mRNA (Wada et aI, 1991; Battey and Wada, 1991). 
Immunohistological studies have confirmed that MBN-like pathways 
are sent out from the suprachiasmatic nucleus. These BN-like projections 
end in adjacent hypothalamic and thalamic regions (Watts and Swanson, 
1987). Therefore, BN may affect circadian regulation through its effects 
on GRP receptors localized in the suprachiasmatic nucleus. BN may also 
affect circadian functions indirectly through its effects on other thalamic 
and hypothalamic regions. 
BN effects on thermoregulation 
ICV BN administration lowers body temperature when animals are kept 
under any of the following conditions: cold ambient temperature (4°C) 
(Brown et aI, 1979); food deprivation; or insulin-induced hypoglycemia 
(Avery and Calis her, 1982; Babcock and Barton, 1989). BN is believed to 
lower the body temperature set point (Stump et aI, 1990), which 
attenuates heat production and enhances heat loss. Two hypothalamic 
nuclei containing GRP receptors, the preoptic nucleus, and the 
paraventricular nucleus (Wada et ai, 1991; Battey and Wada, 1991), may be 
responsible for mediating BN's hypothalamic effects. 
BN microinfusion into the paraventricular nucleus has been shown to 
produce hypothermia if rats are kept either food deprived, or hypoglycemic 
with insulin. Refeeding in either of the conditions restores body 
temperature (Barton and Babcock, 1991; Babcock and Barton, 1990). BN 
microinfusion in the preoptic nucleus has similar effects (Babcock et aI, 
1992). BN's hypothermic effects in the preoptic nucleus have been shown 
to be antagonized with the BN antagonist 'l'BN (Babcock, et aI, 1992), 
supporting the suggestion that BN hypothermic effects are mediated by BN 
receptors. 
IV. BN central effects on feeding and digestive functions 
Central BN administration specifically suppresses feeding at a dose that 
induces behavioral stereotypy (Kulkosky et aI, 1982; McCoy and Avery, 
1990; Meisenberg, 1990; Flynn, 1991). The feeding inhibition results from 
a reduction in the amount eaten, but not in the frequency of eating (Flynn, 
1991). Bilateral injection of BN into the lateral hypothalamus, causes 
modification of post-deprivation feeding (Stuckey and Gibbs, 1982). 
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Micro-injection of BN produces strong suppression of feeding when 
injected into the hypothalamic areas, amygdala, and periaqueductal gray. 
The septum, ventral tegmantal areas, and reticular formation, however, 
are insensitive (Gibbs, 1985; Kyrkouli et aI, 1987; McCoy and Avery, 
1989). In all of these brain areas, BN microinjection increases behavioral 
stereotypy and decreases time spent resting and sleeping (Kyrkouli et aI, 
1987) . 
BN effects on gastric functions involve several systems. ICV BN 
administration inhibits gastric acid output and concentration (Strephens 
et aI, 1991), and gastric contractility in rats (Heymann-Monnikes et aI, 
1990). Central BN effects on gastric contractility can be antagonized by 
. ICV injection of a BN antagonist [N-acetyl-GRP-(20-26)-OCH31 (Heymann-
Monnikes et aI, 1990), indicating the involvement of the autonomic neural 
mechanisms. Microinjected in the dorsal vagal complex, BN alone does not 
modify basal gastric contractility. However, BN inhibits the stimulation 
of gastric contractility induced by a thyrotropin-releasing hormone analog 
microinjected into the dorsal vagal complex (Heymann-Monnikes et aI, 
1990), suggesting that BN participates in the modulation of gastric 
function by interacting with other ligand/receptor system. 
The combined retrograde tracing and immunohistochemical technique, 
and localized BN receptor mRNA expression studies (Wada et aI, 1991) 
provide evidence that links BN receptor functional modification with 
feeding inhibition (Costello et aI, 1991). It has been demonstrated that the 
dorsal vagal complex receives direct projection from the parvocellular 
part of the paraventricular nucleus in the hypothalamus (Costello et aI, 
1991). In the paraventricular nucleus most of the vag ally projecting BN 
immunoreactive neurons are located within the medial parvocellular 
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subdivision (Costello et aI, 1991). BN-like immunoreactivity has also been 
localized within neuronal cell bodies of the hypothalamus and nerve 
terminals within the dorsal vagal complex (Panula et aI, 1982, 1984). It 
has been hypothesized that a functional circuit relating these regions may 
mediate some of the feeding inhibition effects of central BN 
administration (Panula et aI, 1982, 1984). 
v. Theoretic basis of (14C]2DG methodology 
The [14C]2DG method was used to map local metabolism levels in this 
study. The [14C]deoxy-D-glucose ([14C]2DG) method for the measurement of 
LCGU was derived by analysis of a model based on the biochemical 
properties of 2DG in central nervous tissue (Sokoloff et aI, 1977; 1989). 
2DG is transported bidirectionally between blood and brain by the same 
carrier that transports glucose across the blood-brain barrier. In the 
cerebral tissues, it is phosphorylated by hexokinase to 2-deoxyglucose-s-
phosphate (DG-s-P). Deoxyglucose and glucose are competitive substrates 
for both blood-brain transport and hexokinase-catalyzed phosphorylation. 
Unlike glucose-s-phosphate, DG-s-P cannot be converted to fructose-s-
phosphate, and it is also not a substrate for glucose-s-phosphate 
dehydrogenase. Other break down processes are slow, and the metabolites 
(DG -s-P) are relatively stable. The biochemical processing of 2DG is 
therefore stopped at this stage; DG-s-P is trapped in the cerebral tissue 
(Sokoloff et aI, 1989). 
If the DG-s-P accumulation time is kept short enough to allow the 
assumption of negligible loss of [14C] DG-s-P from the neurons, then the 
quantity of [14C]DG-s-P accumulated in cerebral tissue at any given time 
following the introduction of [14C]2DG into the circulation is equal to the 
integral of the rate of [14C]2DG phosphorylation by hexokinase in that 
tissue during the accumulation time. This integral is in turn, related to 
the amount of glucose that has been phosphorylated over the same 
interval, depending on the time course of the relative concentrations of 
[14C]2DG and glucose in the precursor pools and the Michaelis-Menten 
kinetic constants for hexokinase with respect to both (14C]2DG and 
glucose. With glucose consumption in a steady state, the amount of 
glucose phosphorylation during the interval of time equals the steady-
state flux of glucose through the hexokinase-catalyzed step times the 
duration of the interval, and the net rate of flux of glucose through this 
step equals the rate of glucose utilization (Sokoloff et aI, 1989). 
An operational equation (Appendix 2) is derived from the model, 
requiring the flowing assumptions: 
1. Plasma glucose and the rate of cross-membrane glucose 
transportation remain constant throughout the experimental 
period; 
2. Tissue compartment is homogeneous, within which the 
concentrations of [14C]2DG and glucose are uniform and 
exchange directly with the plasma; and 
3. Molecular concentrations of free [14C]2DG are essentially 
equal to zero (Sokoloff et aI, 1989). 
Because the operational equation of the method was derived on the 
basis of the assumption that arterial plasma glucose concentration 
remains constant during the experimental period, the original method is 
applicable only to experiments in which this assumption is satisfied 
(Savaki et aI, 1980; Sokoloff et aI, 1989). If the plasma glucose level is 
unstable, it is required that a modified operational equation is used 
(Appendix 2.) (Savaki et aI, 1980). 
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Chapter 3. Material and Methods: 
Animals 
Male Long-Evans hooded rats (Brock University, St. Catharines, Ontario) 
weighing 270-320 gm were used. Before surgery, the animals were housed 
in group cages and maintained on a 12 hr light:dark cycle (8 am:8 pm) 
under controlled humidity and temperature conditions. Food (Standard Lab 
Chow) and water were available ad libitum. 
Experimental design: 
The research paradigm consisted of a 3 X 2 factorial design with three 
levels of the dose condition and two levels of restraint, totaling 6 
experimental groups (Table 9). 
Table 9. Research paradigm 
Group unrestrained restrained 
Vehicle 8 8 
BN O.1Jlg 8 8 
BN 0.511g 8 8 
Vehicle saline 3 Jll. 
By collapsing the two BN-treated groups and comparing them with 
controls, we tested for the existence of a BN treatment effect. By 
comparing low and medium dose conditions with control, we tested for a 
BN dose effect. 
The restraint condition was designed to distinguish the effects of BN 
treatment on metabolic activities from those induced by motor 
stereotypy. If LCGU is affected in the unrestrained groups but not in the 
restrained groups, it would suggest that the alteration is a result of the 
execution of motor stereotypy. On the other hand, if the restrained and 
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unrestrained groups exhibit similar metabolic responses to BN, it would 
suggest that the alteration is not a result of the execution of motor 
stereotypy. Rather, the alterations is likely caused by BN treatment. 
We tested for effects of restraint or BN upon LCGU by looking for an 
interaction between BN treatment and restraint. An interaction shows 
that the effects of BN upon cerebral metabolism differ over restraint 
conditions, and would prevent us from attributing alterations in 
functional activity to direct effects of BN. 
Animals were randomly assigned to one of the following experimental 
groups (Table 9): (1) free-moving, 0.9% saline 3JlI; (2) free-moving, BN 
0.1 Jlg/3JlI; (3) free-moving, BN 0.5Jlg/3JlI; (4) restrained, 0.9% saline 3JlI; 
(5) restrained, BN 0.1 Jlg/3JlI; and (6) restrained, BN 0.5Jlg/3JlI. The dose 
conditions were chosen according to published studies (for example, 
Merali and Piggins, 1990). At the 0.5 Jlg level, BN can elicit intensive 
grooming behaviors. Higher levels do not further enhance the behavioral 
effects (Rasler 1984). 
Preparation of animals 
Rats were weighed and rectal temperature was recorded prior to surgery. 
Inhalational general anesthesia was induced with 4% halothane carried in 
66% nitrous oxide and 33% oxygen, and maintained with 1.50/0 halothane in 
66% nitrous oxide and 33% oxygen. 
Femoral vessel catheterization. A small incision was made in the skin 
of the right femoral triangle, at the level of the inferior edge of the 
epigastric muscle. A blunt dissection separated subcutaneous connective 
tissue, and a 1.5 cm length of the femoral vessels, just distal to the 
epigastric muscle, was isolated with 2 pairs of 7.5 cm curved, blunt 
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forceps. The same forceps were used to separate the femoral nerve from 
the artery. Three lengths of thread (3/0 silk, Ethicon, Somerville, NJ) 
were placed, one at a time, under each vessel. At the distal end of the 
dissection the vessel was tied off and the thread firmly taped to the 
surgery table. At the medial end of the dissection, the weight of a 
hemostat resting on the surgery table applied slight tension to another 
thread, temporarily occluding the flow of blood. The third thread remained 
unused at this time. 
Microdisection scissors (7.5 cm) were used to cut a small triangular 
opening, extending about one-third the diameter of the vessel, in each 
vessel. A catheter of polyethylene tubing (PE 50, Intramedic Tubing, Clay-
Adams, Parippany, NJ) filled with 0.9% saline solution (to which sodium 
heparin, 100 units/ml, was added to prevent blood coagulation within the 
tubing) and connected to a 3 ml plastic syringe, also filled with 0.9% 
saline solution, was then inserted into each vessel. After being advanced 3 
to 4 cm, the catheter was secured in each vessel with the three threads. 
After securing the intravascular catheters, a 0.5 cm incision was 
made in the skin at the nape of the neck between the scapulae, and a 
hypodermic needle was inserted into the femoral incision and advanced 
subcutaneously to the nape incision around the hind limb. The catheters 
were passed through the hypodermic needle and drawn through the nape 
incision. The catheters were flushed with 0.9% saline, containing sodium 
heparin (100 units ml- 1) to prevent blood coagulation within the tubing, 
and plugged with copper wire. The femoral and cervical incision were 
closed, and the catheters anchored to the skin at the neck with silk suture. 
A small piece of masking tape held the exposed portion of the catheters 
(about 4 cm) in a coil at the neck. 
Third ventricle cannula implantation. Rats were mounted in a Kopf 
stereotaxic instrument with the incisor bar at 3.3 mm below interaural 
zero to achieve a flat skull. General anesthesia was maintained using the 
same combination of anesthetics through a modified plastic mask fitted 
onto the incisor bar. Coordinates for the third ventricle were 4.3mm from 
bregma, O.Omm from the midline, 4.3mm ventral from the straight line 
passing through bregma and lambda (Paxinos and Watson, 1982; Merali and 
Piggins, 1990). 
The point of cannula implantation was opened with a round head 
dental drill. A guide cannula (24 gauge, Plastic Products, Roanoke, VA) 
was implanted in the third ventricle. The guide cannula was then cemented 
to the skull with dental acrylic anchored to 4 jewelers screws. A 
stainless-steel obturator, extending 0.5 mm beyond the tip of the guide 
cannula, was kept in the guide cannula at all times except during 
injection. 
The animals were allowed to recover in a wooden chamber maintained 
at 36°C until emergence. The animals were then returned to the animal 
room and housed individually in metal cages for further recovery. During 
the 48 hr recovery time the animals were maintained on the standard 
light/dark cycle with food and water available ad libitum until the 
experi ment. 
Peptide 
BN (Pennisula Laboratories, Inc., CA) was obtained from Dr. Z Merali 
(School of Psychology, University of Ottawa). Each vial contained 50 flg 
BN, and was stored at -20°C with silica gel until use. For use, BN was 
dissolved with 0.9% saline (vehicle) at the following concentration: (1) 
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SO}lg in 1S00}l1 0.9% saline (0.1 }lg/3}l1); and (2) SO}lg in 300}l1 0.9% 
saline (0.S}lg/3 }ll). 
Experimental procedures 
The animals were weighed and rectal temperature recorded. Those with 
post-surgical body weight loss over 2S% and/or body temperature higher 
then 38.SoC were excluded from the experiment. The artery and vein 
catheters were extended with PE SO tubing to 60 cm and secured to the 
cage. This allowed injection of isotope and blood sampling, while the 
animals moved freely. The animals were familiarized with the clear 
plastic test chamber ( 60 x 30 x 30 cm ) padded with fine wood chips for 
at least S minutes, during which time blood samples were taken for 
baseline plasma glucose and hematocrit. Those with hematocrit lower 
then SO% were eliminated from the study. Lower hematocrit is caused by 
loss of large amount of blood during third ventricle cannulation. 
The obturator was removed from the ventricular cannula immediately 
before injection, and the injector was inserted into the guide cannula. The 
injection tip extended O.S mm beyond the tip of guide cannula within the 
third ventricle. Injection was carried out with a hand held 2S }ll 
microsyringe (Hamilton Co., Reno, NV) at a steady rate for about 1.S to 2 
minutes. The obturator was replaced in the guide cannula after the 
injection. Behavior was then observed for S minutes. Of the animals 
receiving BN, only those which exhibited stereotypic grooming behaviors 
within S minutes after injection proceeded further in the experiment. 
For the unrestrained animals, a computer data logging program 
(OataLog, courtesy of Dr. Z Merali) was used to score animal behavior 
throughout the one hour experimental period, i.e. 1S minutes after ICV 
injection, and 45 minutes 2DG incubation period. Animal behaviors were 
scored in 10 second epochs, according to the definition given in Table 10. 
Table 10. Behaviors assessed and their operational definitions 
Behavior Operational definition 
Head washing The animal licks it's forepaws and wipe 
them over the face and crown regions 
Head scratching The side of the face or nape region is 
contacted by hind limbs 
Body washing The animal licks the ventral and/or 
lateral surfaces of the thorax, abdomen or 
tail 
Body scratching The flanks of the body are contacted by 
hindlimbs 
Anal-genital The animal licks the genital and/or anal 
regions 
Locomotor behavior The animal moves about the cage or 
actively orients to some aspects of the cage 
Rest The animal remains stationary or sleeps 
(Modified from Merali and Piggins, 1990) 
In order to distinguish BN LCGU effects on neural metabolism from 
those induced by bodily movement of behavioral stereotypy, a complete 
immobilization is required. To establish the restraint condition, 
immobilization was performed with a specially designed restraining 
jacket (Figure 3), and animals were further wrapped in a hand towel. 
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Figure 3. Restraining jacket with measurements 
(Shown smaller than actual size). 
Measures were taken to ensure unrestricted breathing. A certain 
degree of head and forelimb movement was possible but any locomotion 
and grooming behavior was completely prohibited. Restrained animals 
were immobilized for 15 minutes before initiation of the 2DG experiment 
to match the time course used in freely moving animals. 
2DG (100 J.lCi kg-1 in heparinized 0.9% saline) was injected through the 
venous catheter. Blood samples were taken in 50 J.l1 capillaries (Fisher 
Scientific, Pittsburgh; PAl at 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 10, 15, 20, 
30, and 45, minutes and spun in a centrifuge (Brinkmann Inc.) for 3 
minutes, after which hematocrit was measured (packed red blood cell 
volume/total blood volume). Plasma (20 J.l1 aliquots) was taken from the 
centrifuged samples, mixed with 7 ml of scintillation fluid (Scintiverse, 
E. Fisher) and counted in a Beckman model 1800 liquid scintillation 
35 
3 6 
counter (Beckman Instrument Inc., Fullerton, CA). Counting efficiency was 
determined and quench correlation was performed. 
Additional blood samples (30 - 40 JlI) were collected in Eppendorf 
microvials at 0, 1, 2, 3, 4, 5, 10, 15, 20, 30, and 45 minutes, and spun in a 
centrifuge (Brinkmann Inc.). In these samples, plasma glucose was 
enzymatically assayed using a Beckman Glucose Analyzer-2 (Beckman 
Instrument Inc., Fullerton, CA). 
After the 45 minute 2[14C]-DG incubation period, the animals were 
killed with a lethal dose of sodium pentobarbital delivered via the arterial 
catheter. The animals were decapitated with a small animal decapitator, 
and the brain was extracted from the skull within 5 minutes and frozen in 
2-methylbutane chilled to -45 to -60°C on dry ice. The time interval from 
the 45 minute sample to complete freezing of the brain was within 8 
minutes. The extracted brains were wrapped in aluminum foil, placed in a 
small glass jar filled with dry ice, and stored at -80°C until sectioning. 
For sectioning, the brains were mounted on an object holder with M-1 
embedding matrix (Upshow, Mich.) and cut at 20 microns on a cryostat 
(Riechert-Jung, Model 3200A, Germany) within 36 hours after the run. The 
chamber temperature of the cryostat was maintained at -20 to -22°C; the 
temperature of the object holder was -14 to -16°C. Sections were picked 
up on hot (60°C) micro slides. The slides were placed on a hot plate (60°C) 
under a hair dryer. They were left under these conditions of moderate heat 
and warm air for at least 30 seconds. This procedure was taken to reduce 
isotope diffusion during the drying process. All the slides remained on the 
hot plate for at least 6 minutes. 
Image analysis 
The sections were then placed in contact with Kodak SB-5 blue X-ray film 
(SB-5, Kodak, Rochester; CN) for 20-24 days with [14C]methylmethacrylate 
standards (Amersham). Following development of the film, 
autoradiographs were analyzed for LCGU using a computer image analyzer 
(MCID, M1; Imaging Research, Inc., St. Catharines, ON). The rate and lump 
constants were those described for the conscious rat (Sokoloff et aI, 
1989). Blood integrals were calculated with the modified 2DG method 
(Savaki et aI, 1980). 
Statistical analyses 
The datalogging data were normalized using the total animal activity 
score (grooming/total, locomotion/total, rest/total), and expressed as a 
percentage of total activity for further processing. 
The normalized behavioral data during the 1 hr experiment period, 
blood glucose data before and after [14C]2DG injection, and LCGU data were 
analyzed using analysis of variance (AN OVA) on SPSS-PC+, version 2.0. 
Two-way ANOVA was employed to test for overall main effects (BN 
treatment, restraint) and interaction. A BN treatment effect indicates 
that a difference in LCGU exists among BN treatment conditions. A 
restraint effect signifies that a difference in LCGU exists among the 
restraint conditions. An interaction effect indicates that the BN 
treatment effect is dependent upon the restraint conditions, or vice versa. 
Multiple comparisons for one-factor (Group 1-6; one-way AN OVA) 
were used to compare individual groups. The Tukey's honestly significant 
difference (HSD) was used. In this analysis, the difference of treatment is 
37 
the only variable. The results of this analysis indicate the existence of a 
difference between individual groups. 
One-way ANOVA for repetitive measurements was used to compare 
blood glucose changes before and after BN administration. 
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Chapter 4. Results 
Animal physical conditions 
We did not observe significant differences between any BN treatment and 
restraint conditions in pre-surgery body weight, pre-surgery body 
temperature, surgery time, recovery time allowed, pre-experiment body 
weight, and pre-experiment body temperature (p>O.05, two-way AN OVA) 
(Table 11). There was no interaction effect between any of the 
experimental conditions either. 
Table 11. Physical conditions of the experimental animals 
(Mean+S.E.; n=8 unless missing value is indicated.) 
Physical Vehicle BN 0.1 J.lg BN 0.5J.lg Vehicle BN 0.1 J.lg BN 0.5J.lg 
Conditions Unrestr. Unrestr. Unrestr. Restr. Restr. Restr. 
Pre-
surgery 
Wt. 
gm 30 1 .00 297.50 297. 1 3 299 .88 294 .00 299.00 
±3.57 ±4.67 ±5.88 ±4.33 ±4.26 ±6.48 
Pre - OC 
Surgery 
Temp. 
Surgery min 
Time 
Recovery h r 
Duration 
Pre- gm 
experiment 
Wt. 
37.03 
±0.17 
103.75 
±07.95 
63.92 
±8.65 
277.50 
±5.55 
Pre- OC 37.46 
experiment ±0.09 
Temp. 
m One missing value. 
36.96 
±0.17 
133.13 
±12.10 
47.49 
±3.92 
265.13 
±6.33 
37.46 
±0.22 
37.23 
±0.15 
105.00 
±06.34 
47.75 
±2.97 
269.38 
±7.54 
37.21 
±0.13 
108.75 
±08.39 
49.85 
±4.37 
268.88 
±5.04 
37.64 m37 .7 
±0.16 ±0.15 
37.24 
±0.29 
105.63 
±04.57 
48.14 
±2.57 
259.38 
±4.64 
37.79 
±0.16 
37.31 
±0.15 
124.38 
±09.13 
48.58 
±4.12 
268.63 
±5.05 
37.49 
±0.16 
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Behavioral observation 
The distribution of behaviors the unrestrained vehicle group is shown in 
Table 10. Locomotor behaviors were coordinated without agitation. 
Occasional grooming activities were well coordinated. In most cases 
grooming included head washing and body licking, and head and body 
scratching. Exploring and grooming were separated by intervals where 
animals showed no obvious physical movement (resting). The inactive 
period may be followed by sleeping (typical sleeping position, eyes 
closed). 
In the BN (0.5Jlg/3JlI) unrestrained group, animals were in a 
constantly active state, except for brief rest periods. Locomotion was 
agitated (Table 12). Not all of the exploring activities appeared 
coordinated; a good part of the locomotor activities occurred in intervals 
between bursts of grooming behaviors. Locomotor behaviors also included 
chewing behavior and "wet dog shakes". Grooming appeared in abrupt 
bursts, which were frequently interrupted by brief locomotion or rest 
episodes. The rest period also seemed to be divided into two episodes: rest 
followed by overt grooming, and locomotor behaviors; and short pauses 
during vigorous grooming. In the BN 0.1 Jlg group (Table 12) treated 
unrestrained group, behavior was similar to the BN 0.5Jlg group, while 
grooming and locomotor behaviors were manifested at a lower level (Table 
12). Sleep was absent in both of the BN treated groups. 
BN treatment increased total grooming time and decreased time spent 
resting during the 1 hr observation period (p<0.01, ANOVA) (Table 12). 
Using multiple comparison techniques, difference between individual 
groups was identified. They are shown in Table 12. 
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Most animals in the three restrained groups appeared quiet after BN 
injection. Some of the saline treated animals even had observable sleep 
periods (complete quiet, eyes closed). In all of the BN treated animals, 
there were occasional attempts to move the neck and the forepaws. 
Occasional episodes of struggling could be seen in all animals. No 
grooming behaviors were observed. 
Table 12. Effects of BN on behavior (Mean±S.E.; n=8.) 
Behavior Groups 
Vehicle BN 0.1ug BN O.Sug 
Grooming 04.7 4±0.90 2S .OS±3 .36 ** 46.09±3.88**, tt 
Locomotor 
behaviors 47.71 ±4.61 32 .22±4 .60* 30 .6S±2 .27** 
Rest 47.S6±4.84 42.77±2.17 22.81±2.63**,tt 
* p<O.OS, ** p<0.01 comparing with vehicle; 
t p<O.OS, tt p<0.01 comparing with BN 0.1 J.lg. 
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Blood Glucose Measurement 
Blood glucose data before and after lev injection are shown in Table 13, 
and Figure 4. There was no significant BN treatment effect nor restraint 
effect (p>0.05; two-way ANOVA) in the zero time sample before BN lev 
injection (base line) among all of the experimental conditions (Table 13). 
In the two vehicle groups, unrestrained animals showed a significant 
decrease in blood glucose after lev injection (p<0.01; one-way ANOVA) 
(Table 13; Figure 4) due to food deprivation during experiment. In the two 
BN 0.1 J..Lg groups, BN injections caused significant increase in blood 
glucose in both restraint conditions (p<0.01; one-way ANOVA) (Table 13; 
Figure 4). The two BN 0.5J..Lg groups showed similar changes as in BN 0.1 
groups (Table 13; Figure 4). 
Table 13. Effect of BN on blood glucose level (mg/dl) 
(Mean±S.E.; n=8 unless missing value is indicated.) 
Time Vehicle BN 0.1)lg BN 0.5 )lg Vehicle BN 0.1)lg BN 0.5 )lg Unrestr. Unrestr. Unrestr. Restr. Restr. Restr. 
Before 
ICV 
injection 
150.29m 
±4.22 
148.88 
±4.38 
145.71m 
±3.19 
154.57m 
±2.97 
155.00 
±5.42 
153.25 
±3.72 
AfterlCV 135.24§ 187.32** 202.25** 154.69 187.72** 205.12** 
injection +0.90 +2.49 +2.70 +2.15 +4.29 +2.83 
m One missing value. 
§ p<0.01 comparing with the blood glucose levels before intracerebro-
ventricular injections (lower); 
** p<0.01 comparing with the blood glucose levels before intracerebro-
ventricular injections (higher). 
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Figure 4. Comparison of blood glucose before and after ICV injection. 
Abbreviations: UR: unrestrained; R: restrained. 
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Whole brain glucose utilization 
We did not observe any effect of BN treatment or restraint on overall 
cerebral metabolism rate (WB CGU) (p>0.05; two-way ANOVA) (Table 14). 
Table 14. BN effect on whole brain glucose utilization 
(WB CGU, Ilmol 100 go, min-') (Mean±S.E.; n=8.) 
Structures Vehicle BN 0.1Jlg BN 0.5Jlg Vehicle BN 0.1Jlg BN 0.5Jlg 
Unrestr. Unrestr. Unrestr. Restr. Restr. Restr. 
WB 42.04 
+1.88 
41.12 
+2.09 
37.30 
+1.13 
38.45 
+2.05 
Local cerebral glucose utilization Measurement 
39.14 
+4.23 
39.19 
+2.11 
Across the three categories, there was no interaction between the effects 
of BN dose and the effects of restraint on local cerebral glucose 
utilization (LCGU) (p>0.05, two-way ANOVA). Data from the same BN 
treatment conditions (unrestrained and restrained) were therefore 
collapsed into three BN treatment groups, i.e. vehicle, BN 0.1 J.-lg, BN 0.5J.-lg 
to test for BN treatment effects. Similarly, data from all the three BN 
treatment conditions were collapsed to test for restraint effects. 
Primary Regions. Collapsed data show that, among the four anterior 
thalamic subdivisions (our primary category), the anteroventral thalamic 
nucleus (AV) (p=0.029, two-way ANOVA), and the anteroventral thalamic 
nucleus, ventral lateral portion (AVVL) (p<0.0005, two-way ANOVA) 
exhibited significant response to BN treatment (Table 15; Figures 5, 6). 
However, no main effect for restraint or interaction effects between BN 
treatment and restraint was observed in these two regions (p>0.05, two-
way ANOVA). Diagrams of the rat brain coronal section show our sampling 
locations (Figure 7). 
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Table 15. BN treatment effect on LCGU: Primary structures 
Structures 
PO 
AM 
AV 
AWL 
BN treatment effect* 
+ 
+++ 
+ p<0.05, ++ p<0.01, +++ p<0.001. 
Abbreviations: 
AD: anterodorsal thalamic nucleus; 
AM: anteromedial thalamic nucleus; 
AV: anteroventral thalamic nucleus; 
Restraint effectt 
AVVL: anteroventral thalamic nucleus, ventral lateral portion. 
* Data were collapsed across the two restraint conditions and the 
two dose conditions (0.1 I1g and 0.5 I1g) to show BN treatment 
effects (two-way ANOVA); 
t Data were collapsed across the three dose conditions (vehicle, 
BN 0.1 I1g and 0.5 I1g) to show restraint effects (two-way 
ANOVA). 
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Figure 5. Primary regions: AD, AM, AVVL, 
AV. LCGU for vehicle, BN 0.1 I-1g, BN 
0.5 I-1g groups. Data are collapsed 
across two restraint conditions into 
three dose conditions to compare BN 
treatment effects. 
* p<0.05, ** p<0.01 comparing with 
vehicle groups. 
Abbreviations: 
AD: anterodorsal thalamic nucleus; 
AM: anteromedial thalamic nucleus; 
AV: anteroventral thalamic nucleus; 
AVVL: anteroventral thalamic nucleus, 
ventral lateral portion. 
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Figure 6. Gray scale [14C]2DG image illustrating increased LCGU in 
anteroventral thalamic nucleus and its ventral lateral portion after BN 
administration. The top image represents BN 0.5 ~g, unrestrained 
animals; the bottom image represents vehicle, unrestrained animals. 
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Figure 7. Coronal section of the rat brain at the level of the anterior 
thalamus, showing the sampling locations for AV, AD, AVVL, LDVL 
(Interaural 7.20 mm, Bregma 1.80 mm) (Modified from Paxinos and 
Watson, 1989). 
Abbreviations: 
AD: anterodorsal thalamic nucleus; 
AM: anteromedial thalamic nucleus; 
AV: anteroventral thalamic nucleus; 
AVVL: anteroventral thalamic nucleus, ventral lateral portion; 
BLA: basolateral amygdaloid nucleus, anterior part; 
DG: dentate gyrus; 
LDVL: lateral dorsal thalamic nucleus, dorsal medial; 
MD: mediodorsal thalamic nucleus; 
MeA: medial amygdaloid nucleus; 
Pe: periventricular hypothalamic nucleus; 
SCh: suprachiasmatic nucleus. 
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Multiple comparison techniques (Tukey HSD) revealed alterations in 
LCGU caused by differences in individual experimental conditions in AV 
and AVVL (Figures 8, 9). 
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Figure 8. Anteroventral thalamic nucleus, 
ventral lateral portion: LCGU for 
unrestrained and restrained animals 
treated with BN 0.5 ~g, BN 0.1 ~g, and 
vehicle. 
* p<O.OS comparing with unrestrained 
vehicle group; 
t p<O.OS comparing with restrained 
vehicle group. 
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Secondary Regions. Data collapsed across the restraint conditions 
show a BN treatment effect in the internal granular layer of the olfactory 
bulb (IGr) and the suprachiasmatic nucleus (SCh) (p=0.028, p=0.003, 
respectively, two-way ANOVA) (Table 16; Figures 10, 11). No restraint 
effect or interaction effect was found in these regions. Diagrams of the 
rat brain coronal section show our sampling locations (Figures 12, 13). 
Table 16. BN treatment effect on LCGU: Secondary structures 
Structures 
IGr 
Mi 
Tu 
NcDL 
Acb 
03 
S 
Sf 
BLA 
La 
MeA 
PMCo 
MD 
Pe 
SCh 
LC 
Sol 
SubGel 
BN treatment effect* Restraint effectt 
+ 
++ 
+ p<O.OS, ++ p<0.01, +++ p<0.001. 
Abbreviations: (See page 6; Appendix I). 
* Data were collapsed across the two restraint conditions and 
the two dose conditions (0.1 Ilg and O.S Ilg) to show BN 
treatment effects (two-way ANOVA); 
t Data were collapsed across the three dose conditions (vehicle, 
BN 0.1 Ilg and 0.5 Ilg) to show restraint effects (two-way 
ANOVA). 
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125~----------------------------~ 
IGr Hi Tu NcDL 
Cerebral Regions 
D Vehicle I[J BN O.1119 II BN O.511g 
Figure 10. Secondary regions: IGr, Mi, Tu, 
NcDL. LCGU for vehicle, BN 0.1 1l9, BN 
0.5 Ilg groups. Data are collapsed across 
two restraint conditions into three dose 
conditions to compare BN treatment 
effects. 
* p<0.05, ** p<0.01 comparing with 
vehicle groups. 
Abbreviations: 
IGr: internal granular layer of the olfactory bulb; 
Mi: mitral cell layer of the olfactory bulb; 
Tu: olfactory tubercle; 
NcDL: deep layer of neocortex. 
52 
"""' c 
'E 
....... 
0> 
0 
0 
.-
-'0 
E 
::1-
"'--" 
::::> 
C> 
u 
-I 
125.-----------------------------, 
100 
75 
50 
25 
MD Pe SCh 
Cerebral Re9ions 
D Vehicle [ill] BNO.lIl9 m BNO.51l9 
Figure 11. Secondary regions: MD, Pe, 
SCh. LCGU for vehicle, BN 0.1 Jlg, BN 
O.S Jlg groups. Data are collapsed 
across two restraint conditions into 
three dose conditions to compare BN 
treatment effects. 
* p<O.OS, ** p<0.01 comparing with 
vehicle groups. 
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II-.I-f-- Hi 
Figure 12. Coronal section of the rat 
brain at the level of the olfactory 
bulb, showing the sampling 
locations for IGr, and Mi 
(Interaural 15.70 mm, Bregma 
6.70 mm) (Modified from Paxinos 
and Watson, 1989). 
Abbreviations: 
IGr: internal granular layer of the 
olfactory bulb; 
Mi: mitral cell layer of the 
olfactory bulb. 
AD 
~ ....... .....n,~'t~~,..----Jtr----T AWL 
AM 
Figure 13. Coronal section of the rat brain at the level of the anterior 
thalamus, showing the sampling location for SCh (Interaural 7.60 
mm, Bregma 1.40 mm) (Modified from Paxinos and Watson, 1989). 
Abbreviations: 
AD: anterodorsal thalamic nucleus; 
AM: anteromedial thalamic nucleus; 
AVVL: anteroventral thalamic nucleus, ventral lateral portion; 
SCh: suprachiasmatic nucleus. 
54 
Tertiary Regions. Data collapsed across the restraint conditions show 
a significant treatment effect in the median eminence (ME) (p=O.011; two-
way ANOVA) (Table 17, Figure 14). No main effects for restraint or 
interaction effect was found in this region (p>O.05, two-way ANOVA). 
Diagrams of the rat brain coronal section show our sampling locations 
(Figure 17). 
Table 17. BN treatment effect on LCGU: Tertiary structures 
Structures BN treatment effect* Restraint effectt 
Cg1 
Cg2 
Cg3 
Hi 
Ent 
LDDM 
LDVL 
VL 
VM 
VPL 
VPM 
L.G 
VMH 
DM 
LH 
PH 
Arc 
InfS 
ME 
MM 
LM 
3 
EC 
+ 
+ p<0.05, ++ p<0.01, +++ p<0.001. 
Abbreviations: (See Page 7; Appendix I). 
+ 
+ 
+ 
* Data were collapsed across the two restraint conditions and the 
two dose conditions (0.1 Ilg and 0.5 Ilg) to show BN treatment 
effects (two-way AN OVA) ; 
t Data were collapsed across the three dose conditions (vehicle, BN 
0.1 Ilg and 0.5 Ilg) to show restraint effects (two-way ANOVA). 
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Figure 14. Tertiary regions: Arc, InfS, ME. 
LCGU for vehicle, BN 0.1 I1g, BN 0.5 I1g 
groups. Data are collapsed across two 
restraint conditions into three dose 
conditions to compare BN treatment 
effects. 
* p<0.05, ** p<0.01 comparing with 
vehicle groups. 
Abbreviations: 
Arc: arcuate hypothalamic nucleus; 
InfS: infundibular stem; 
ME: median eminence. 
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Multiple comparison techniques (Tukey HSD) revealed alterations in 
LCGU caused by differences in individual experimental conditions in ME 
(Figure 15). 
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Figure 15. Median eminence (ME): LCGU for 
unrestrained and restrained animals 
treated with BN 0.5 J.1g, BN 0.1 J.1g, and 
vehicle. 
t p<0.05 comparing with restrained vehicle 
group. 
Based on data collapsed across the three dose conditions, a restraint 
effect was found in both of the laterodorsal thalamic nucleus (LD) 
subdivisions, including its dorsomedial portion (LOOM) (p=O.044) and 
ventrolateral portion (LDVL) (p=O.009). A restraint effect was also found 
in lateral geniculate (LG) (p=O.027) (two-way ANOVA) (Table 17, Figure 
16). No main effect for BN treatment or interaction between BN treatment 
and restraint was found in these regions (p>O.OS, two-way ANOVA) . 
Diagrams of the rat brain coronal section show our sampling locations for 
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LOOM, and LOVL (Figure 17). 
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Figure 16. Tertiary regions: LOOM, 
LOVL, LG, 3, SC. Oata are 
collapsed into two restraint 
conditions to compare restraint 
effects. 
* p<O.05, ** p<O.01 comparing 
with unrestrained groups. 
Abbreviations: 
LOOM: lateral dorsal thalamic 
nucleus, dorsal medial; 
LOVL: lateral dorsal thalamic 
nucleus, ventral lateral; 
LG: lateral geniculate; 
3: oculomotor nucleus; 
SC: superior colliculus. 
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Figure 17. Coronal section of the rat brain at the level of the laterodorsal thalamus, 
showing the sampling locations for LOOM, LOVL, ME (Interaural 6.20 mm, Bregma 
2.80 mm) (Modified from Paxinos and Watson, 1989). 
Abbreviations: 
Arc: arcuate hypothalamic nucleus; 
LOOM: lateral dorsal thalamic nucleus, dorsal medial; 
LOVL: lateral dorsal thalamic nucleus, ventral lateral; 
ME: median eminence; 
VMH: ventromedial hypothalamic nucleus. 
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Chapter 5. Discussion 
The main objective of our study was to localize the functional effects of 
BN within the CNS. A large number of regions were mapped with the 
[14C]2DG method, and we had to conduct statistical tests for each region. 
Essentially, each region was an independent experiment. Therefore, it was 
possible that we would come across some significant findings purely by 
chance. In order to minimize the chance of type I error in the regions we 
were most interested in, we organized cerebral regions into three 
categories, namely the primary regions, the secondary regions, and the 
tertiary regions. The primary regions were of most interest based on our 
previous findings of BN effects in the anterior thalamus. The secondary 
regions were of interest because they have been shown to have high 
concentrations of BN receptors. The tertiary regions were chosen based on 
the association of these regions with the limbic system, the thalamus, 
and the hypothalamus. Subcortical visual structures were also included 
due to their association with animal locomotion. 
Using this categorization, we can decrease the number of regions 
tested within each category and, therefore decrease the chance of 
including a statistical artifact within the primary and secondary 
categories. Since the primary regions, in particular, only needed four 
tests, the p values can be examined with greater confidence that they are 
not a statistical artifact. 
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The anteroventral thalamic nucleus, especially its ventral lateral portion, 
shows increased metabolic activity following BN administration 
We found strong BN treatment effects in AV, especially in AVVL. These 
effects were not influenced by behavioral restraint that completely 
prohibited the animals from exhibiting behavioral stereotypy. Therefore, 
in AV and AVVl, regional alterations in lCGU reflected BN influences upon 
cerebral function. They did not result from BN-induced behavioral 
stereotypy. 
We have found no published data regarding BN receptor distribution in 
AVVL. Our observation of increased lCGU in AV, especially in AVVl, 
probably reflects BN-induced functional alterations arising elsewhere and 
projecting to the anterior thalamus. This suggestion of a remote origin for 
the observed effects should be examined in context of the neuroanatomy of 
the limbic circuitry and the hypothalamic regions, and the distribution of 
BN receptors. 
One possible origin of projections to the anterior thalamus is the 
hypothalamus. As the principle limbic synaptic relay for information 
reaching the limbic cortex (Kelly and Dodd, 1991; Kupfermann, 1991 a), the 
anterior thalamus receives projections from the mammillary bodies and 
hypothalamus via the mammillothalamic tract (tract of Vicq-d'Azyr) 
(MTT) (Maclean , 1986). It also receives neural projections directly from 
the hippocampus via the fornix and indirectly from the hippocampus via 
the fornix-mammilary complex pathway (Figure 18) (Faull and Mehler, 
1985; Kupfermann, 1991 a). 
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Figure 18. The limbic circuitry. The limbic circuit originally 
proposed by James Papez is indicated by thick lines; more 
recently described connections are shown by fine lines. 
(Modified from Kupfermann, 1991 a). 
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Neural afferents from other limbic regions usually project to a 
specific subdivision of the anterior thalamus (Figure 19) (Isaacson, 1974). 
Hippocampal projections to the anterior thalamus pass via the fornix 
mainly to AV and AM. The mammillary complex projects via MTT to AV, AM 
and AD; in particular, the medial mammillary nucleus projects bilaterally 
to AD. Afferents from both the cingulate cortex and the retrosplenial 
granular cortex terminate in AV and AM (Faull and Mehler, 1985; Isaacson, 
1974). AChE staining studies have shown that AVVL receives fiber 
projections from MTT, especially in the caudal ventromedial region where 
it is often dispersed by fiber fascicles from MTT (Figure 19) (Faull and 
Mehler, 1985). We have been unable to find data regarding synaptic 
projections to AVVL, and would suggest that further study of projections 
to this region might be useful in localizing BN's sites of action upon the 
eNS. 
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Figure 19. Neural projections to the 
anterior thalamus subdivisions. Thick 
lines indicate projections that may be 
involved in the transmission of BN-
induced effects from the hippocampus, 
and hypothalamus; fine lines indicate 
projections to other subdivisions (From 
Faull and Mehler, 1985; Isaacson, 
1974). 
Abbreviation: 
A V: anteroventral thalamic nucleus; 
AM: anteromedial thalamic nucleus; 
AD: anterodorsal thalamic nucleus; 
A VVL: ventral lateral portion of AV. 
It has been suggested that BN receptors, located in the hypothalamic 
regions, the hippocampus, and amygdala (Zarbin et aI, 1985; Moody et aI, 
1988; Battey and Wada, 1991), mediate BN-induced behavioral stereotypy. 
Our data suggest that AV, especially AVVL should be added to the list 
structures involved in the mediation of behavioral stereotypy. 
The strong influence of BN upon functional activity in the anterior 
thalamus may be linked to stereotypy. It has been demonstrated that 
animals with MTT lesions are slow or reluctant to begin new behavioral 
acts (Isaacson, 1974), indicating that the interruption of the neural 
pathway from the mammillary complex to the anterior thalamus 
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attenuates the initiation of novel behaviors. Since destruction of the MTT 
induces effects which are the opposite of BN-induced behavioral 
stereotypy, it is suggested that MTT may conduct BN-induced functional 
alterations from the hippocampus, amygdala, and hypothalamic regions to 
the anterior thalamus. 
Increased metabolic activities in the ventral lateral portion of the 
anteroventral thalamic nucleus may reflect altered cholinergic activities 
in this region during alterations of limbic and hypothalamic functioning 
AChE delineates fiber terminals that contain acetylcholine (Paxinos and 
Watson, 1989). AV displays a high level of AChE activity especially in its 
ventrolateral portion (AVVL), whereas AD and AM are characterized by, 
respectively, moderate and low levels of AChE activity (Faull and Mehler, 
1985; Paxinos and Watson, 1989). AV is also characterized by its high 
cellular density; the cells are generally very closely packed, except in the 
caudal ventromedial region where they are often dispersed by fiber 
fascicles from MTT (Figure 19) (Faull and Mehler, 1985). High AChE 
activity and high density of fiber fascicles from MTT suggest that AVVL 
may contain a large cholinergic synaptic field, which receives neural 
terminals mainly from MTT. 
Based on the histological composition of AV, especially its ventral 
lateral part, and our observations of BN-induced metabolic alterations in 
this region, it is suggested that metabolic alterations in AVVL reflect 
increased synaptic activity in this region. As maintenance of cellular 
homeostasis in association with EPSPs and/or IPSPs (the active pumps) 
are the major energy expenditure of the neurons, increased LCGU in AVVL 
reflects increased energy consumption caused by greater amount of EPSP 
and/or IPSP activities at the synapses within AVVL. Given the high 
density of AChE activities in AVVL, it is further suggested that increased 
EPSP and/or IPSP in AVVL is mediated by cholinergic synapses. 
Behavioral stereotypy induced by BN and other neural peptides may be 
mediated by the same neural circuitry 
Other neuropeptides, e.g. ACTH, TRH, and SP, can also cause stereotypic 
grooming and locomotion when given centrally (Gmerek and Cowan, 1983; 
Cowan et aI, 1985; Van Wimersama Greidanus et aI, 1988; Meisenberg and 
Simmons, 1986). The fact that completely different peptides can cause a 
similar behavioral stereotypy that only differs in details suggests that 
various neural peptides induce behavioral stereotypy through a common 
neural circuitry. 
Therefore, it would be of interest to study the central effects of 
ACTH, TRH, SP on cerebral metabolism in AV, and AVVL. If the central 
administration of these peptides can induce alterations of LCGU in AV, 
especially in AVVL, the suggestion that the behavioral stereotypy induced 
by these peptides is mediated by common neural circuitry would be 
supported. 
Increased metabolic activities in the suprachiasmatic nucleus may reflect 
altered functional state of BN receptors in the nucleus and surrounding 
regions 
We found that central BN administration caused increased metabolic 
activity in SCh. This effect did not interact with physical restraint. 
Therefore, the SCh findings represent direct BN effects, and not secondary 
manifestations of motor activity. It is likely that the effect results from 
BN interaction with the high MBN receptor density in SCh (Table 2). 
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As the primary biological clock in mammals, SCh functions as an 
internal circadian pacemaker (Kelly, 1991), and may be responsible for the 
maintenance of circadian rhythms of sleep, locomotion, feeding and 
drinking, and adrenal corticosterone secretion (Kelly, 1991; Bleier and 
Byne, 1985). All of these functions are affected by central BN 
administration. 
Immunohistological studies have confirmed that SCh has mutual 
projections with surrounding hypothalamic regions, as well as some 
remote structures such as the thalamus and hippocampus. Some of these 
projections contain BN-like immunoreactivities (Watts and Swanson, 
1987; Mikkelsen, et ai, 1991). Because of the widespread presence of BN 
receptors in the hypothalamus and hippocampus (Battey and Wada, 1991), 
and because of reciprocal projections between SCh and these regions 
(Watts and Swanson, 1987), functional alterations in SCh may contribute 
to the disruption of circadian rhythms observed following BN 
administration. 
Increased metabolic activities in the internal granular layer of the 
olfactory bulb may be caused by alterations of bombesin receptor function 
IGr exhibited a BN-induced increase in LCGU. We failed to see a restraint 
effect or interaction between treatment and restraint. Therefore, the 
effects observed in IGr are caused by BN central administration and are a 
direct result of BN influence upon neural function. 
Our findings of BN-induced metabolic alterations in IGr agree with in 
vitro [125 1_ Tyr4]BN autoradiographic binding studies showing high BN-
receptor densities in the olfactory bulb (Table 2) (Zarbin et ai, 1985; 
Moody et ai, 1988). In situ hybridization studies performed with cDNA 
66 
67 
specific probes demonstrated that NMB receptor mRNA and NMB mRNA 
expression was most prominent in the olfactory regions (Wada et aI, 1991, 
Battey and Wada, 1991). Because of the high densities of NMB receptor 
distributions in the olfactory region, it is suggested that increased 
metabolism in IGr is the reflection of BN effects upon BN receptors in this 
region. 
Increased metabolic activities in the median eminence may reflect 
bombesin effects on receptors localized on parvocellular neurons 
ME exhibited a BN-induced increase in LCGU. We failed to see a restraint 
effect or interaction between treatment and restraint in ME. Therefore, 
the effects observed in ME are caused by BN central administration and are 
a direct result of BN influence upon cerebral function. 
As a part of the pituitary portal system, ME receives projections from 
parvocellular neurons in the following hypothalamic regions: the 
paraventricular nuclei (or infundibular nucleus), periventricular region, 
medial basal region, arcuate and tuberal nuclei, and preoptic nuclei (Figure 
20) (Bleier and Byne, 1985; Armstrong, 1985; Kupfermann, 1991 a). 
Among the hypothalamic regions that contain parvocellular neurons, 
the periventricular nucleus has been demonstrated to have high 
concentrations of 1251-[Tyr4]BN bindings (GRP and/or NMB receptors) 
(Moody et aI, 1990; Zarbin et aI, 1985). In addition, the paraventricular 
nucleus has been demonstrated to express GRP mRNA, and to express GRP 
receptor mRNA very strongly (Wad a et aI, 1990; Wada et aI, 1991; Battey 
and Wada, 1991) (Figure 20). Projections of these regions to ME may 
underlie the effects we observed in this region. 
Pituitary stalk 
~~~-++- Median eminence 
Long portal vesse ls ""7'"''----:1.-'/ 
Neurohy pophy sis 
--+ 
! Short portal vessels 
Figure 20. Role of GRP receptors in modulating parvocellular neuron 
releasing functions. lev BN binds to GRP receptors on the 
parvocellular neuron surface. Stimulated neurons secrete releasing 
or inhibiting hormone in ME, or modulate secretion of another 
neuroendocrine neuron. (Modified from Kupfermann, 1991 a). 
Functional alterations of the hyppocampus after BN central 
administration could also have effects on endocrine functions, since 
autoradiography studies in the rat have provided evidence of fibers from 
the ventral subiculum reaching the "medial preoptic-anterior 
hypothalamus area" and terminating in the ventral medial and arcuate 
nuclei (Maclean, 1985). 
Central BN administration is associated with increased blood level of 
ACTH (Sander, 1991), GH (Bitar et aI, 1991; Houben and Denef, 1990), and 
TSH (Malendowicz and Miskowiak, 1990). The releasing and inhibiting 
neurohormones or precursor peptides for these anterior pituitary 
hormones are synthesized in the parvocellular neurons and packaged in 
neurosecretory vesicles, and then transported down the axon to the 
68 
69 
terminal, where they are stored and released by secretion to the ME portal 
vasculature (Figure 20) (Kupfermann, 1991 a; Schwartz, 1991). Our 
findings that BN treatment increases LCGU in ME support the hypothesis 
that increased neural transportation and enhanced exocytosis in ME 
increases energy consumption in this region. 
Dopamine is the only non-peptide inhibiting hormone released in ME. It 
has been shown that BN and GRP increase the concentration of dopamine 
metabolites in ME and in the intermediate lobe of the pituitary 
(Manzanares et aI, 1991). Following BN administration, increased 
dopaminergic IPSPs in the tuberoinfundibular neurons may be a part of the 
increased metabolic rate in ME. 
Physical restraint may inhibit emotional expression in the animals 
By comparing combined data (collapsed across the vehicle and the two BN 
doses) from restrained animals with combined data from the unrestrained 
animals, we found that restraint resulted in lowered metabolic activities 
in LD, which includes LOOM and LDVL. 
Anatomically, LD lies just caudolateral to the anterior thalamus, and 
peripheral to the internal medullary lamina (Faull and Mehler, 1985) . 
Although LD is not considered a core component of the limbic circuitry, it 
has projections to the limbic regions (Kelly and Dodd, 1991), and the 
posterior cortical areas (Faull and Mehler, 1985). Functionally, it 
participates in the mediation of emotional expression in the mammals 
(Kelly and Dodd, 1991). 
Emotional experiences are functions of the cingulate cortex, the 
temporal lobe, and the orbitofrontal cortex (Kupfermann, 1991 b), whereas 
the behavioral expression of the emotion needs the participation of 
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subcortical limbic structures (Isaacson, 1974). Our observation that 
behavioral restraint decreased metabolic rate in LD, supports the 
suggestion that the mediation of animal's expression of emotions is 
participated in by LD, and that the animal's emotional state can be 
reflected in animal behaviors. 
Physical restraint may reduce neural activities in the visual pathways 
Similarly, by comparing combined data from restrained animals with that 
of the unrestrained animals, we found that behavioral restraint is 
associated with a decrease in LCGU in LG. In comparison, an earlier study 
showed that complete restraint increased LCGU in LG, although other 
subcortical visual structures were not affected (Bryan Jr et ai, 1983). The 
discrepancy could result from the difference in restraining techniques. In 
the earlier study, the restraint was achieved using a neuromuscular 
blocker in awake animals. In our study, the animals were restrained using 
a jacket which is believed to be less stressful. It is suggested that the 
form of immobilization in our study may have reduced visual processing 
requirements in the animals . 
Notes on methodology 
An assumption of the operational equation of the [14C]2DG method is that 
arterial plasma glucose concentration remains stable during the 
experimental period (Savaki et ai, 1980; Sokoloff et ai, 1989). Due to BN-
induced hyperglycemia, the original operational equation is not applicable 
to lev BN studies. We therefore calculated LCGU using the modified 
operational equation (Appendix 2.) (Savaki et ai, 1980) which compensates 
for the effects of blood glucose fluctuation. 
The classic quantitative [14C]2DG method uses partial restraint to 
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facilitate blood sampling, reduce catheter dead space, and minimize the 
risk of damage to the catheters by the animals (Sokoloff et aI, 1986; 
Crane and Porrino, 1989). Partially restrained animals show signs of 
stress, including vocalization, excessive elimination, and struggling. The 
plasma glucose levels are also higher than in freely-moving animals 
(Crane and Porrino, 1985). 
We did not use partial restraint. Instead, complete physical restraint 
was used. Previously reported LCGU effects of complete restraint in 
awake, paralyzed, and artificially ventilated animals (Bryan Jr et aI, 
1983) can be compared with our data. It is believed that the stress 
induced by a neuromuscular blocker in an awake animal is severe, as 
artificial ventilation through an intratracheal intubation is very painful, 
especially when the restraint is maintained over a 45 min period. 
Restraint by a cloth jacket can hardly be considered comfortable. One of 
the signs of stress is that plasma glucose decrease after ICV injection in 
unrestrained vehicle animals (due to food deprivation during the 
experiment) was compensated by the restraint or BN central 
administration (Table 13; Figure 4). 
Conclusions 
Central bombesin (BN) administration induces a syndrome of stereotypic 
grooming and locomotion in rats. BN receptor mapping studies have 
provided clues as to the location of BN's central sites of action. We used 
the [14C]deoxyglucose method to map regional functional activity following 
BN intracisternal injection, in both freely moving and restrained rats. 
Glucose utilization levels increased in the anteroventral thalamic nucleus, 
especially its ventral lateral portion, suprachiasmatic nucleus, internal 
granular layer of the olfactory bulb, and median eminence. These effects 
were present under both restraint conditions, and did not result from BN-
induced behavioral stereotypy. Therefore, it is suggested that the 
metabolic alterations result from functional alterations BN receptors, and 
from the actions of BN-containing neurons upon their terminal projection 
fields. In particular, projections of BN receptor containing neurons affect 
cholinergic synaptic activity in the anterior thalamus. 
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Appendices: 
I. Key for Abbreviations 
Abbreviations are in alphabetic order. 
Cerebral structures: 
3 
Acb 
PD 
PM 
Arc 
AV 
AWL 
BLA 
Cg1 
Cg2 
Cg3 
m 
OM 
Ent 
Hi 
IGr 
InfS 
La 
LC 
LOOM 
LOVL 
L.G 
LH 
LM 
MO 
ME 
MeA 
Mi 
MM 
NcOL 
Pe 
PH 
PMCo 
S 
s::; 
SCh 
Sf 
Sol 
SubGel 
Tu 
VL 
VM 
VMH 
VPL 
VPM 
oculomotor nucleus (bulbular) 
accumbens nucleus (limbic) 
anterodorsal thalamic nucleus (thalamic) 
anteromedial thalamic nucleus (thalamic) 
arcuate hypothalamic nucleus (hypothalamic) 
anteroventral thalamic nucleus (thalamic) 
anteroventral thalamic nucleus, ventral lateral (thalamic) 
basolateral amygdaloid nucleus, anterior part (limbic) 
cingulate cortex, area 1 (limbic) 
cingulate cortex, area 2 (limbic) 
cingulate cortex, area 3 (limbic) 
dentate gyrus (limbic) 
dorsal medial hypothalamic nucleus (hypothalamic) 
entorhinal cortex (limbic) 
hippocampus (limbic) 
internal granular layer of the olfactory bulb (sensory: olfactory) 
infundibular stem (hypothalamic) 
lateral amygdaloid nucleus (limbic) 
locus ceruleus (bulbular: reticular) 
lateral dorsal thalamic nucleus, dorsal medial (thalamic) 
lateral dorsal thalamic nucleus, ventral lateral (thalamic) 
lateral geniculate (thalamic) 
lateral hypothalamic area (hypothalamic) 
lateral mammillary nucleus (hypothalamic) 
mediaodorsal thalamic nucleus (thalamic) 
median eminence (hypothalamic) 
medial amygdaloid nucleus (limbic) 
mitral cell layer of the olfactory bulb (sensory: olfactory) 
medial mammillary nucleus, medial part (hypothalamic) 
deep layer of neocortex (cortical) 
periventricular hypothalamic nucleus (hypothalamic) 
posterior hypothalamic area (hypothalamic) 
posteromedial cortical amygdaloid nucleus (limbic) 
subiculum (limbic) 
superior colliculus (limbic) 
suprachiasmatic nucleus (hypothalamic) 
stria termilanis nucleus (limbic) 
nucleus of the solitary tract (bulbular: reticular) 
substantia gelitinosa (spinal) 
olfactory tubercle (sensory: olfactory) 
ventral lateral thalamic nucleus (thalamic) 
ventromedial thalamic nucleus (thalamic) 
ventromedial hypothalamic nucleus (hypothalamic) 
ventral posterolateral thalamic nucleus (thalamic) 
ventral postomedial thalamic nucleus (thalamic) 
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Peptides: 
1251_G RP 1251-labeled gastrin-releasing peptide 
AClH adrenocorticotropic hormone 
ACTH1_24 adrenocorticotropic hormone 1-24* 
aMSH a-melanocyte-stimulating hormone 
BN bombesin 
BN6_3 bombesin 6-3; BN specific antagonist 
C R -1 409 specific CCK antagonist 
G-I growth hormone 
ffiP gastrin releasing peptides 
GRP1-16 gastrin releasing peptides 1-16, GRP antagonist 
GRP14-27 gastrin releasing peptides 14-27 
MBNs mammalian bombesin-like peptides 
NMB neuromedin B 
NMB30 neuromedin B 30 
NMB32 neuromedin B 32 
NMC neuromedin C 
SP substance P 
TRH thyrotropin releasing hormone 
TSH thyroid stimulating hormone 
",BN** [Leu13 ",(CH2NH) Leu14]BN 
[125 1_Tyr4] BN* 
iodine 125 labeled tyrosine BN 
[125 1_Tyr4] NMB 
iodine 125 labeled tyrosine NMB 
[D-Arg1 D- Trp7,9 Leu 11 ]SP 
span tide BN antagonist 
* Numbers refer to the amino acid position from the N-terminus; 
** the", symbol indicates substitution of a reduced peptide bond at the indicated 
site i.e. CONH changes to CH2NH 
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Biochemical substances: 
2DG 
5-HT 
6-0HDA 
A01E 
cAMP 
cGMP 
DG-6 - P 
G-6-P 
Gt\BA. 
LCGU 
[14C]2DG 
[14C]DG-6-P 
2-deoxyglucose 
5-hydroxytryptamine 
6-hydroxydopamine 
acetylcholinesterase 
cyclic adenosine monophosphate 
cyclic guanosine monophosphate 
2-deoxyglucose-6-phosphate 
glucose-6-phosphate 
y-aminobutyric acid 
local cerebral glucose utilization 
[14C]deoxy-D-glucose 
[14C]deoxy-g I ucose-6-phosphate 
Abbreviations for Amino Acids: 
Ala alanine 
Arg arginine 
Asn asparagine 
Cpa p-chlorophenylalanine 
Gin glutamine 
Glu glutamic acid 
Gly glycine 
His histamine 
Leu leucine 
Met methionine 
pGlu pyroglutamic acid 
Phe phenylalanine 
Pro proline 
Th r threonine 
Trp tryptophan 
Ty r tyrosine 
Val valine 
Other: 
ICV intracerebraoventricular 
LCGU local cerebral glucose utilization 
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II. Equations used in LCGU calculation 
General Equation for Measurement of Reaction Rates with Tracers: 
Labeled Product Formed in Interval of Time I a to T 
Rate of Reaction = 
[ Isotope Effect 1 [ Integrated Specific Activity 1 
Correction Factor of Precursor 
Operation Equation of [14CjDeoxyglucose Method: 
Labeled Product Formed in interval of Time, 0 to T 
,~ ____________ ~A~ __________ ~, 
Total 14C in Tissue 14C in Precursor Remaining in Tissue 
at time, T at Time, T 
~ / A~ __________ ~, 
* * T * * S* (T) - ~ e-(k2 +k3)T Ie Cp e (k2 +k3)t dt 
~=--------------------~--~---------------AV~~ [rT ~l dt-e-(k; +k~)T rT[~} (k~ +k~)t dt 
ctJV mKm ~o cP Jo cP 
'-y-----/ '-v-----" ' V / 
Isotope Effect Integrated Plasma 
Correction Factor Specific Activity 
Correction for Lag in Tissue 
Equilibration with Plasma 
'~------------~v~----------~' 
Integrated Precursor Specific Activity in Tissue 
Modified Operational Equation: 
* * * * _ft * * * Ci (t) - kl e xp- (~+k3 ):'0 Cp exp (k2 +k3 )t dt 
Ri=--------~--------------------------~--------------------------~-
* * * * iT * * * * (Jc +k3 ) e xp- (k_ +k3 )T C exp (k2 +k3 ) t dt 
.?V mKm it 2 2 0 P 
----------------------------~------------------------- dT 
* T ~v K 0 i 
m m Cp (0) exp- (k2 +k3 )T + (k2 +k3) exp- (k2 +k3 )T 0 Cpexp (k2 +k3) t d 
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III. LCGU for the structures used in this study 
Local cerebral glucose utilization (LCGU, pmol/100g/min): 
Primary' structures (Mean±S.E.; n=82. 
Structures Vehicle BN 0.1119 BN O.5l1g Vehicle BN 0.1119 BN 0.5119 
Unrestr. Unrestr. Unrestr. Restr. Restr. Restr. 
PO 66.45 78.50 68.87 53.42 66.45 71.55 
±1.72 ±8.64 ±3.67 ±3.03 ±7.80 ±4.79 
NJt 59.87 62.11 54.46 54.66 62.30 63.46 
±2.78 ±5.35 ±1.27 ±4.01 ±8.76 ±5.10 
AV 69.68 85.23 71.65 53.79 70.51 76.69 
±2.87 ±9.27 ±3.64 ±3.32 ±8.50 ±5.61 
AWL 73.45 108.00 116.61 61.26 100.36 106.83 
+3.58 +12.22 +4.51 +3.94 +13.26 +8.15 
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Local cerebral glucose utilization (LCGU, j.lmol/1 ~Og/min): 
Secondar~ structures (Mean±S.E.; n=8l. 
Structures Vehicle BN 0.1Jlg BN 0.5Jlg Vehicle BN 0.1Jlg BN 0.5Jlg 
Unrestr. Unrestr. Unrestr. Restr. Restr. Restr. 
IGr 61.38 74.59 63.36 61.65 88.75 74.18 
±4.31 ±10.77 ±4.94 ±3.13 ±11.63 ±8.49 
Mi 61.85 69.20 61.70 57.97 84.24 68.50 
±5.83 ±10.05 ±5.82 ±3.33 ±10.79 ±7.46 
Tu 55.91 65.24 56.43 59.52 52.92 60.41 
±4.52 ±4.48 ±4.01 ±5.36 ±6.50 ±3.51 
NcDL 50.37 44.98 41.30 45.38 43.59 43.78 
±4.55 ±4.91 ±3.72 ±4.06 ±5.63 ±3.66 
Am 46.65 49.16 43.48 47.59 45.06 47.89 
±4.75 ±3.35 ±2.34 ±3.93 ±5.93 ±3.34 
D3 32.16 34.44 29.33 29.06 33.01 30.38 
±3.41 ±3.39 ±2.26 ±1.71 ±2.59 ±1.59 
S 50.19 49.91 40.58 41.77 42.86 42.97 
±3.81 ±4.57 ±2.55 ±3.43 ±4.03 ±3.49 
ST 27.86 31.80 31.38 25.78 26.31 28.27 
±3.19 ±3.51 ±2.09 ±1.68 ±2.96 ±2.69 
BLA 51.53 46.15 47.22 46.37 48.39 48.73 
±3.87 ±4.13 ±2.42 ±2.93 ±6.46 ±2.98 
La 35.65 33.67 33.91 35.14 34.51 34.37 
±2.89 ±3.67 ±2.14 ±1.77 ±5.05 ±2.46 
MeA 33.00 33.15 34.80 34.40 38.55 34.71 
±2.91 ±2.22 ±2.94 ±2.37 ±4.98 ±3.00 
PMCo 38.86 42.80 34.80 38.75 45.41 43.66 
±3.88 ±1.93 ±2.72 ±2.61 ±4.43 ±2.94 
MD 60.94 59.95 58.01 54.28 61.16 59.50 
±4.31 ±6.02 ±3.44 ±2.82 ±7.74 ±4.80 
Pe 28.52 28.89 26.97 30.64 28.77 29.73 
±2.75 ±2.54 ±1.29 ±1.62 ±2.75 ±2.39 
E:Ch 33.47 40.66 47.32 34.45 39.90 50.96 
±1.65 ±3.89 ±4.84 ±2.37 ±5.25 ±5.24 
LC 47.75 41.68 43.75 43.04 46.93 43.63 
±5.22 ±2.86 ±2.22 ±3.31 ±5.93 ±1.94 
Sol 41.97 35.44 34.8 36.88 41.71 35.06 
±2.72 ±2.91 ±2.65 ±2.51 ±6.00 ±7.67 
SubGel 41.17 49.98 43.83 39.37 55.87 58.94 
+3.94 +5.72 +5.92 +3.57 +6.92 +6.94 
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Local cerebral glucose utilization (LeGU, J.lmo//1 ~Og/min) 
Tertiary" structures (Mean±S.E.; n=8.1 
Structures Vehicle BN 0.1 J.Lg BN 0.5J.Lg Vehicle BN 0.1 J.Lg BN 0.5J.Lg 
Unrestr. Unrestr. Unrestr. Restr. Restr. Restr. 
Cg1 59.96 55.22 51.73 56.51 53.73 58.18 
±6.31 ±5.18 ±4.02 ±4.97 ±6.52 ±3.98 
Cg2 55.59 54.46 50.26 55.37 49.46 54.31 
±5.27 ±5.64 ±3.39 ±4.94 ±5.83 ±3.66 
Cg3 52.64 53.07 48.19 53.66 55.5 52.83 
±5.67 ±4.47 ±4.09 ±4.15 ±7.89 ±3.93 
Hi 41.19 39.44 34.02 38.34 41.59 38.99 
±3.00 ±2.09 ±1.82 ±2.26 ±5.97 ±2.51 
Ent 41.49 43.16 35.05 38.49 44.83 43.81 
±3.44 ±3.56 ±1.84 ±2.38 ±5.22 ±3.35 
LOOM 60.26 60.48 62.67 50.7 54.68 54.00 
±4.31 ±4.77 ±2.80 ±2.81 ±7.78 ±4.00 
LOVL 57.64 59.20 63.7 45.40 53.26 50.01 
±4.11 ±4.69 ±4.40 ±1.99 ±7.88 ±3.42 
VL 62.02 60.00 62.45 53.02 55.31 57.94 
±4.38 ±4.45 ±2.57 ±2.51 ±6.45 ±4.36 
VM 68.08 65.98 64.85 58.54 63.19 62.85 
±3.76 ±5.31 ±3.18 ±3.32 ±8.42 ±3.93 
VPL 58.12 54.12 59.72 48.14 50.49 49.85 
±4.61 ±4 .30 ±3.26 ±2.54 ±7.34 ±3.93 
VPM 57.88 55.98 59.31 49.79 51.62 48.45 
±5.44 ±3 .31 ±5.42 ±3.35 ±6.38 ±3.03 
LG 62.65 68.42 58.49 49.19 55.50 60.33 
±3.93 ±4.15 ±3.99 ±2.60 ±6.41 ±4.26 
VMH 31.94 29.50 32.59 32.97 37.23 34.99 
±2.93 ±2.16 ±2.90 ±1.62 ±5.23 ±2.89 
OM 36.89 33.07 30.96 35.48 37.25 33.20 
±3.07 ±1.73 ±2.59 ±1.40 ±2.73 ±3.07 
LH 37.93 39.23 38.03 40.47 40.87 36.38 
±3 .11 ±3.55 ±2.60 ±3.89 ±4.84 ±2.49 
PH 39.38 39.69 31.76 38.97 42.12 39.03 
+4.24 +3.10 +3.46 +2.79 +5.19 +3.74 
(continued) 
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{continue} 
Structures Vehicle BN 0.1Jlg BN 0.5Jlg Vehicle BN 0.1Jlg BN 0.5Jlg 
Unrestr. Unrestr. Unrestr. Restr. Restr. Restr. 
Arc 28.89 30.89 36.81 33.21 38.79 35.04 
±2.58 ±1.98 ±4.00 ±2.03 ±4.24 ±3.58 
InfS 29.30 38.93 42.38 38.35 40.25 46.46 
±3.62 ±2.52 ±4.05 ±3.87 ±7.15 ±4.88 
ME 35.39 45.32 59.12 41.49 47.50 56.63 
±2.32 ±5.16 ±5.96 ±5.66 ±8.20 ±7.83 
MM 80.77 90.18 75.67 64.24 86.41 83.90 
±5.00 ±7.59 ±4.42 ±3.55 ±11 .60 ±6.66 
LM 79.24 88.43 77.40 56 .1 7 84 .09 76.15 
±5.92 ±7.58 ±5.25 ±3.03 ±11.04 ±6.73 
3 67.03 66.91 54.95 53.37 60.09 61.71 
±4.36 ±7.06 ±3.77 ±4.40 ±6.12 ±4.74 
g) 57.09 58.38 45.85 48.19 52.68 52.49 
+3.03 ±4.34 ±3.58 ±3 .65 ±5.17 ±4.87 
